CN115702150A - CD73 inhibitor and application thereof in medicine - Google Patents
CD73 inhibitor and application thereof in medicine Download PDFInfo
- Publication number
- CN115702150A CN115702150A CN202180043145.8A CN202180043145A CN115702150A CN 115702150 A CN115702150 A CN 115702150A CN 202180043145 A CN202180043145 A CN 202180043145A CN 115702150 A CN115702150 A CN 115702150A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- synthesis
- radical
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims description 5
- 229940127272 CD73 inhibitor Drugs 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 327
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- -1 hydroxy, amino Chemical group 0.000 claims description 71
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 239000012830 cancer therapeutic Substances 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 269
- 239000000243 solution Substances 0.000 description 186
- 230000015572 biosynthetic process Effects 0.000 description 185
- 238000003786 synthesis reaction Methods 0.000 description 185
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 171
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 164
- 239000007787 solid Substances 0.000 description 112
- 238000012544 monitoring process Methods 0.000 description 95
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 92
- 239000000203 mixture Substances 0.000 description 90
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 84
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 80
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 62
- 238000001035 drying Methods 0.000 description 62
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 60
- 238000004440 column chromatography Methods 0.000 description 59
- 239000012043 crude product Substances 0.000 description 54
- 238000002156 mixing Methods 0.000 description 50
- 238000005406 washing Methods 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 37
- 239000000047 product Substances 0.000 description 35
- 238000004537 pulping Methods 0.000 description 34
- UPZFLZYXYGBAPL-UHFFFAOYSA-N 2-ethyl-2-methyl-1,3-dioxolane Chemical compound CCC1(C)OCCO1 UPZFLZYXYGBAPL-UHFFFAOYSA-N 0.000 description 31
- 238000004809 thin layer chromatography Methods 0.000 description 31
- 238000001914 filtration Methods 0.000 description 30
- 238000001816 cooling Methods 0.000 description 29
- 238000000746 purification Methods 0.000 description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 21
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 19
- 239000012074 organic phase Substances 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- 238000007865 diluting Methods 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 239000012299 nitrogen atmosphere Substances 0.000 description 14
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 13
- 238000000926 separation method Methods 0.000 description 12
- 230000007935 neutral effect Effects 0.000 description 11
- 238000012746 preparative thin layer chromatography Methods 0.000 description 11
- 239000012065 filter cake Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 238000000967 suction filtration Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 102100022464 5'-nucleotidase Human genes 0.000 description 5
- KWLOIDOKWUESNM-UHFFFAOYSA-N 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NN1 KWLOIDOKWUESNM-UHFFFAOYSA-N 0.000 description 5
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 4
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 4
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 4
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940125758 compound 15 Drugs 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 239000011345 viscous material Substances 0.000 description 4
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- LKGKUACPLXCVOF-UHFFFAOYSA-N (2,4-dimethoxypyrimidin-5-yl)boronic acid Chemical compound COC1=NC=C(B(O)O)C(OC)=N1 LKGKUACPLXCVOF-UHFFFAOYSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 3
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 3
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 3
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 3
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 3
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 3
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 3
- PPPXRIUHKCOOMU-UHFFFAOYSA-N 1-(benzenesulfonyl)pyrrole Chemical compound C1=CC=CN1S(=O)(=O)C1=CC=CC=C1 PPPXRIUHKCOOMU-UHFFFAOYSA-N 0.000 description 3
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 3
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 3
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 229940127007 Compound 39 Drugs 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 3
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 3
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 229940125846 compound 25 Drugs 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 229940127204 compound 29 Drugs 0.000 description 3
- 229940125877 compound 31 Drugs 0.000 description 3
- 229940125878 compound 36 Drugs 0.000 description 3
- 229940125807 compound 37 Drugs 0.000 description 3
- 229940126540 compound 41 Drugs 0.000 description 3
- 229940125936 compound 42 Drugs 0.000 description 3
- 229940125844 compound 46 Drugs 0.000 description 3
- 229940127271 compound 49 Drugs 0.000 description 3
- 229940126545 compound 53 Drugs 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 3
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 2
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 2
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 2
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 206010024438 Lichenification Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 2
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- YUHSMQQNPRLEEJ-UHFFFAOYSA-N methyl 3-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC(CBr)=C1 YUHSMQQNPRLEEJ-UHFFFAOYSA-N 0.000 description 2
- NLWBJPPMPLPZIE-UHFFFAOYSA-N methyl 4-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1 NLWBJPPMPLPZIE-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 206010042863 synovial sarcoma Diseases 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- GWFIZBYDIHGZRJ-UHFFFAOYSA-N tri(propan-2-yl)-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrol-1-yl]silane Chemical compound CC(C)[Si](C(C)C)(C(C)C)N1C=CC(B2OC(C)(C)C(C)(C)O2)=C1 GWFIZBYDIHGZRJ-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- KHMVLRILJIEAKG-UHFFFAOYSA-N (4-methoxyphenyl)-(1h-pyrrol-3-yl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CNC=C1 KHMVLRILJIEAKG-UHFFFAOYSA-N 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- TUNSVUOTVLWNQT-UHFFFAOYSA-N 1-(bromomethyl)-2-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=CC=C1CBr TUNSVUOTVLWNQT-UHFFFAOYSA-N 0.000 description 1
- QSIVWRRHVXSDNE-UHFFFAOYSA-N 1-(bromomethyl)-3-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=CC(CBr)=C1 QSIVWRRHVXSDNE-UHFFFAOYSA-N 0.000 description 1
- ZKSOJQDNSNJIQW-UHFFFAOYSA-N 1-(bromomethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CBr)=C1 ZKSOJQDNSNJIQW-UHFFFAOYSA-N 0.000 description 1
- KQNBRMUBPRGXSL-UHFFFAOYSA-N 1-(bromomethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(CBr)C=C1 KQNBRMUBPRGXSL-UHFFFAOYSA-N 0.000 description 1
- WZRKSPFYXUXINF-UHFFFAOYSA-N 1-(bromomethyl)-4-methylbenzene Chemical compound CC1=CC=C(CBr)C=C1 WZRKSPFYXUXINF-UHFFFAOYSA-N 0.000 description 1
- XPGHWBDZNQUUQD-UHFFFAOYSA-N 1-(chloromethyl)-2,4-difluorobenzene Chemical compound FC1=CC=C(CCl)C(F)=C1 XPGHWBDZNQUUQD-UHFFFAOYSA-N 0.000 description 1
- BBXDMCQDLOCXRA-UHFFFAOYSA-N 1-(chloromethyl)-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1CCl BBXDMCQDLOCXRA-UHFFFAOYSA-N 0.000 description 1
- VQRBXYBBGHOGFT-UHFFFAOYSA-N 1-(chloromethyl)-2-methylbenzene Chemical compound CC1=CC=CC=C1CCl VQRBXYBBGHOGFT-UHFFFAOYSA-N 0.000 description 1
- XGASTRVQNVVYIZ-UHFFFAOYSA-N 1-(chloromethyl)-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(CCl)=C1 XGASTRVQNVVYIZ-UHFFFAOYSA-N 0.000 description 1
- LZBOHNCMCCSTJX-UHFFFAOYSA-N 1-(chloromethyl)-3-methylbenzene Chemical compound CC1=CC=CC(CCl)=C1 LZBOHNCMCCSTJX-UHFFFAOYSA-N 0.000 description 1
- DCLMJYZEOSDVCL-UHFFFAOYSA-N 1-(chloromethyl)-4-ethoxybenzene Chemical compound CCOC1=CC=C(CCl)C=C1 DCLMJYZEOSDVCL-UHFFFAOYSA-N 0.000 description 1
- DMHZDOTYAVHSEH-UHFFFAOYSA-N 1-(chloromethyl)-4-methylbenzene Chemical compound CC1=CC=C(CCl)C=C1 DMHZDOTYAVHSEH-UHFFFAOYSA-N 0.000 description 1
- GTLWADFFABIGAE-UHFFFAOYSA-N 1-chloroethylbenzene Chemical compound CC(Cl)C1=CC=CC=C1 GTLWADFFABIGAE-UHFFFAOYSA-N 0.000 description 1
- BJMSXWLXFYZHIU-UHFFFAOYSA-N 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CN1C=CC(B2OC(C)(C)C(C)(C)O2)=N1 BJMSXWLXFYZHIU-UHFFFAOYSA-N 0.000 description 1
- MOKUQYSJYISPJS-UHFFFAOYSA-N 1-phenyl-2h-pyridine Chemical compound C1C=CC=CN1C1=CC=CC=C1 MOKUQYSJYISPJS-UHFFFAOYSA-N 0.000 description 1
- LWGNAJWTBRYFJZ-UHFFFAOYSA-N 1-propan-2-yl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CC(C)N1C=CC(B2OC(C)(C)C(C)(C)O2)=N1 LWGNAJWTBRYFJZ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- QDQFMWJAIVSHSG-UHFFFAOYSA-N 2-(2H-benzotriazol-4-yl)-7H-purin-6-amine Chemical compound N1N=NC2=C1C=CC=C2C1=NC(=C2NC=NC2=N1)N QDQFMWJAIVSHSG-UHFFFAOYSA-N 0.000 description 1
- MXOPKPMEGUYUCV-UHFFFAOYSA-N 2-(chloromethyl)-5-methylpyridine Chemical compound CC1=CC=C(CCl)N=C1 MXOPKPMEGUYUCV-UHFFFAOYSA-N 0.000 description 1
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- DHOBZYGMEYEAEM-UHFFFAOYSA-N 3-(chloromethyl)-1-methylpyrazole Chemical compound CN1C=CC(CCl)=N1 DHOBZYGMEYEAEM-UHFFFAOYSA-N 0.000 description 1
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 1
- SWLRTVHQASOVRZ-UHFFFAOYSA-N 4,6-dichloro-3-methylpyridazine Chemical compound CC1=NN=C(Cl)C=C1Cl SWLRTVHQASOVRZ-UHFFFAOYSA-N 0.000 description 1
- OCJNEHCUEUJQGA-UHFFFAOYSA-N 4-(1H-pyrrole-3-carbonyl)benzonitrile Chemical compound N#CC(C=C1)=CC=C1C(C1=CNC=C1)=O OCJNEHCUEUJQGA-UHFFFAOYSA-N 0.000 description 1
- TVOJIBGZFYMWDT-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CNN=C1 TVOJIBGZFYMWDT-UHFFFAOYSA-N 0.000 description 1
- KRLKXOLFFQWKPZ-UHFFFAOYSA-N 4-(bromomethyl)pyridine Chemical compound BrCC1=CC=NC=C1 KRLKXOLFFQWKPZ-UHFFFAOYSA-N 0.000 description 1
- HBJIJFADGURZGI-UHFFFAOYSA-N 4-(chloromethyl)-3-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC=C1CCl HBJIJFADGURZGI-UHFFFAOYSA-N 0.000 description 1
- LOQLDQJTSMKBJU-UHFFFAOYSA-N 4-(chloromethyl)benzonitrile Chemical compound ClCC1=CC=C(C#N)C=C1 LOQLDQJTSMKBJU-UHFFFAOYSA-N 0.000 description 1
- OLSKQWRLRYMCAO-UHFFFAOYSA-N 4-(chloromethyl)quinoline Chemical compound C1=CC=C2C(CCl)=CC=NC2=C1 OLSKQWRLRYMCAO-UHFFFAOYSA-N 0.000 description 1
- BMASTHFFAMGJKZ-UHFFFAOYSA-N 4-bromo-1,2-dihydropyridazine-3,6-dione Chemical compound BrC1=CC(=O)NNC1=O BMASTHFFAMGJKZ-UHFFFAOYSA-N 0.000 description 1
- FGOWNGCSUSKHQI-UHFFFAOYSA-N 4-bromo-6-chloropyridazin-3-amine Chemical compound NC1=NN=C(Cl)C=C1Br FGOWNGCSUSKHQI-UHFFFAOYSA-N 0.000 description 1
- USEDMAWWQDFMFY-UHFFFAOYSA-N 4-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C#N)C=C1 USEDMAWWQDFMFY-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- FYUAHNZYTRBXRV-UHFFFAOYSA-N 5-[5-[1-(cyclopentylmethyl)pyrrol-3-yl]-6-methylpyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC2CCCC2)C=C1 FYUAHNZYTRBXRV-UHFFFAOYSA-N 0.000 description 1
- MHTDAZHFAPPXJB-UHFFFAOYSA-N 5-[5-[1-(cyclopropylmethyl)pyrazol-4-yl]-6-methylpyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC2CC2)N=C1 MHTDAZHFAPPXJB-UHFFFAOYSA-N 0.000 description 1
- TVWSITFCFOAWDB-UHFFFAOYSA-N 5-[5-[1-(cyclopropylmethyl)pyrrol-3-yl]-6-methylpyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC2CC2)C=C1 TVWSITFCFOAWDB-UHFFFAOYSA-N 0.000 description 1
- SJYURGHZYNBADJ-UHFFFAOYSA-N 5-[5-[1-[(2,4-difluorophenyl)methyl]pyrrol-3-yl]-6-methylpyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC(C=CC(F)=C2)=C2F)C=C1 SJYURGHZYNBADJ-UHFFFAOYSA-N 0.000 description 1
- RHGYWALLMJVTRW-UHFFFAOYSA-N 5-[5-[1-[(3-hydroxyphenyl)methyl]pyrrol-3-yl]-6-methylpyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC2=CC(O)=CC=C2)C=C1 RHGYWALLMJVTRW-UHFFFAOYSA-N 0.000 description 1
- IUIJQJJKHFMGMO-UHFFFAOYSA-N 5-[5-[1-[(3-methoxyphenyl)methyl]pyrrol-3-yl]-6-methylpyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC2=CC(OC)=CC=C2)C=C1 IUIJQJJKHFMGMO-UHFFFAOYSA-N 0.000 description 1
- BSUVINNMMPGMTH-UHFFFAOYSA-N 5-[5-[1-[(4-aminophenyl)methyl]pyrrol-3-yl]-6-methylpyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC(C=C2)=CC=C2N)C=C1 BSUVINNMMPGMTH-UHFFFAOYSA-N 0.000 description 1
- NCXLYRKUKCNAPB-UHFFFAOYSA-N 5-[5-[1-[(4-chlorophenyl)methyl]pyrazol-3-yl]-6-methylpyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=NN(CC(C=C2)=CC=C2Cl)C=C1 NCXLYRKUKCNAPB-UHFFFAOYSA-N 0.000 description 1
- DYIOEGSXVGNVJC-UHFFFAOYSA-N 5-[5-[1-[(4-chlorophenyl)methyl]pyrazol-4-yl]-6-methylpyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC(C=C2)=CC=C2Cl)N=C1 DYIOEGSXVGNVJC-UHFFFAOYSA-N 0.000 description 1
- ODKAJHOZYPOIGM-UHFFFAOYSA-N 5-[5-[1-[(4-ethoxyphenyl)methyl]pyrrol-3-yl]-6-methylpyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CCOC1=CC=C(CN(C=C2)C=C2C2=C(C)N=NC(C(C(N3)=O)=CNC3=O)=C2)C=C1 ODKAJHOZYPOIGM-UHFFFAOYSA-N 0.000 description 1
- LVHXFTUGRPSTDV-UHFFFAOYSA-N 5-[5-[1-[(4-methoxyphenyl)methyl]pyrrol-3-yl]-6-methylpyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC(C=C2)=CC=C2OC)C=C1 LVHXFTUGRPSTDV-UHFFFAOYSA-N 0.000 description 1
- ODRAURCJMNLLAE-UHFFFAOYSA-N 5-[5-[3-[(4-hydroxyphenyl)methyl]pyrrol-1-yl]-6-methylpyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1N1C=C(CC(C=C2)=CC=C2O)C=C1 ODRAURCJMNLLAE-UHFFFAOYSA-N 0.000 description 1
- QFQSLLONBDVVFQ-UHFFFAOYSA-N 5-[5-[3-[(4-methoxyphenyl)methyl]pyrrol-1-yl]-6-methylpyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1N1C=C(CC(C=C2)=CC=C2OC)C=C1 QFQSLLONBDVVFQ-UHFFFAOYSA-N 0.000 description 1
- HFHQTSYKTQHZPZ-UHFFFAOYSA-N 5-[6-methoxy-5-[1-[(4-methoxyphenyl)methyl]pyrrol-3-yl]pyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound COC1=CC=C(CN(C=C2)C=C2C(C=C(C(C(N2)=O)=CNC2=O)N=N2)=C2OC)C=C1 HFHQTSYKTQHZPZ-UHFFFAOYSA-N 0.000 description 1
- ISLLZRBMLISUML-UHFFFAOYSA-N 5-[6-methyl-5-[1-(1-phenylethyl)pyrrol-3-yl]pyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(C1=CC=CC=C1)N(C=C1)C=C1C1=C(C)N=NC(C(C(N2)=O)=CNC2=O)=C1 ISLLZRBMLISUML-UHFFFAOYSA-N 0.000 description 1
- CJNUPNDGJQRXEP-UHFFFAOYSA-N 5-[6-methyl-5-[1-[(1-methylpyrazol-3-yl)methyl]pyrrol-3-yl]pyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC2=NN(C)C=C2)C=C1 CJNUPNDGJQRXEP-UHFFFAOYSA-N 0.000 description 1
- AADGXCWWKJCKJH-UHFFFAOYSA-N 5-[6-methyl-5-[1-[(3-methylphenyl)methyl]pyrrol-3-yl]pyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC1=CC=CC(CN(C=C2)C=C2C2=C(C)N=NC(C(C(N3)=O)=CNC3=O)=C2)=C1 AADGXCWWKJCKJH-UHFFFAOYSA-N 0.000 description 1
- MMGVJKYXFSNIDI-UHFFFAOYSA-N 5-[6-methyl-5-[1-[(4-methylphenyl)methyl]pyrazol-3-yl]pyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC1=CC=C(CN(C=C2)N=C2C2=C(C)N=NC(C(C(N3)=O)=CNC3=O)=C2)C=C1 MMGVJKYXFSNIDI-UHFFFAOYSA-N 0.000 description 1
- DHQUIIKYWYXEIJ-UHFFFAOYSA-N 5-[6-methyl-5-[1-[(4-methylphenyl)methyl]pyrrol-3-yl]pyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC1=CC=C(CN(C=C2)C=C2C2=C(C)N=NC(C(C(N3)=O)=CNC3=O)=C2)C=C1 DHQUIIKYWYXEIJ-UHFFFAOYSA-N 0.000 description 1
- QOOCZFGQIWJPRN-UHFFFAOYSA-N 5-[6-methyl-5-[1-[(4-methylsulfonylphenyl)methyl]pyrrol-3-yl]pyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC(C=C2)=CC=C2S(C)(=O)=O)C=C1 QOOCZFGQIWJPRN-UHFFFAOYSA-N 0.000 description 1
- WHIJDNXRICFTED-UHFFFAOYSA-N 5-[6-methyl-5-[1-[(5-methylpyridin-2-yl)methyl]pyrrol-3-yl]pyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC1=CN=C(CN(C=C2)C=C2C2=C(C)N=NC(C(C(N3)=O)=CNC3=O)=C2)C=C1 WHIJDNXRICFTED-UHFFFAOYSA-N 0.000 description 1
- YFIDMJOOKVQFKI-UHFFFAOYSA-N 5-[6-methyl-5-[1-[[2-(trifluoromethoxy)phenyl]methyl]pyrrol-3-yl]pyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC(C=CC=C2)=C2OC(F)(F)F)C=C1 YFIDMJOOKVQFKI-UHFFFAOYSA-N 0.000 description 1
- IYDQMJYWBRWZEJ-UHFFFAOYSA-N 5-[6-methyl-5-[1-[[2-(trifluoromethyl)phenyl]methyl]pyrrol-3-yl]pyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC2=C(C(F)(F)F)C=CC=C2)C=C1 IYDQMJYWBRWZEJ-UHFFFAOYSA-N 0.000 description 1
- CBGAVWRJRQHVCN-UHFFFAOYSA-N 5-[6-methyl-5-[1-[[3-(trifluoromethoxy)phenyl]methyl]pyrrol-3-yl]pyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC2=CC(OC(F)(F)F)=CC=C2)C=C1 CBGAVWRJRQHVCN-UHFFFAOYSA-N 0.000 description 1
- VHJDWFZBEFCISF-UHFFFAOYSA-N 5-[6-methyl-5-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrrol-3-yl]pyridazin-3-yl]-1H-pyrimidine-2,4-dione Chemical compound CC(N=NC(C(C(N1)=O)=CNC1=O)=C1)=C1C1=CN(CC2=CC(C(F)(F)F)=CC=C2)C=C1 VHJDWFZBEFCISF-UHFFFAOYSA-N 0.000 description 1
- QWCGOMIAXFNYIV-UHFFFAOYSA-N 6-(bromomethyl)pyridine-3-carbonitrile Chemical compound BrCC1=CC=C(C#N)C=N1 QWCGOMIAXFNYIV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000006278 bromobenzyl group Chemical group 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- OMEGHMBBBTYRFT-UHFFFAOYSA-N chloromethylcyclohexane Chemical compound ClCC1CCCCC1 OMEGHMBBBTYRFT-UHFFFAOYSA-N 0.000 description 1
- NQIIILQXTJXSCA-UHFFFAOYSA-N chloromethylcyclopentane Chemical compound ClCC1CCCC1 NQIIILQXTJXSCA-UHFFFAOYSA-N 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 229940045803 cuprous chloride Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- CYEFKCRAAGLNHW-UHFFFAOYSA-N furan-3-ylboronic acid Chemical compound OB(O)C=1C=COC=1 CYEFKCRAAGLNHW-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- KGCNHWXDPDPSBV-UHFFFAOYSA-N p-nitrobenzyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CCl)C=C1 KGCNHWXDPDPSBV-UHFFFAOYSA-N 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NPCBDQZLUSJKOW-UHFFFAOYSA-M sodium;4-[5-(4-chlorophenyl)-3,4-dihydropyrazol-2-yl]benzenesulfonate Chemical compound [Na+].C1=CC(S(=O)(=O)[O-])=CC=C1N1N=C(C=2C=CC(Cl)=CC=2)CC1 NPCBDQZLUSJKOW-UHFFFAOYSA-M 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- WCNFFKHKJLERFM-UHFFFAOYSA-N thiomorpholinyl sulfone group Chemical group N1(CCSCC1)S(=O)(=O)N1CCSCC1 WCNFFKHKJLERFM-UHFFFAOYSA-N 0.000 description 1
- ZCAGUOCUDGWENZ-UHFFFAOYSA-N thiomorpholinyl sulfoxide group Chemical group N1(CCSCC1)S(=O)N1CCSCC1 ZCAGUOCUDGWENZ-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Provided is a novel compound having a cancer therapeutic activity. Also provided are methods for the preparation of these compounds and pharmaceutical compositions comprising them.
Description
The present invention relates to a CD73 inhibitor having cancer therapeutic activity. The invention also relates to a preparation method of the compounds and a pharmaceutical composition containing the compounds.
Extracellular 5' -nucleotidase (CD 73) is a glycoprotein on the cell membrane, and is present on the surface of the cell membrane of various cell types, including endothelial cells, lymphocytes, stromal cells, tumor cells, and the like. CD73 catalyzes the production of adenosine from extracellular adenosine 5 '-phosphate (5' -AMP), which induces immunosuppressive effects and promotes tumor proliferation and/or metastasis. In addition, CD73 can also promote tumorigenesis by non-immune related mechanisms, such as promoting tumor angiogenesis, promoting adhesion of tumor cells to extracellular matrix proteins, and the like. Clinically, high levels of CD73 expression are associated with lymph node metastasis and poor prognosis for a variety of cancer types, and CD73 has been found to be an independent prognostic factor in prostate and triple negative breast cancer patients. The invention provides a micromolecular CD73 inhibitor with a novel structure, which has good anti-tumor activity.
Disclosure of Invention
The invention provides a compound shown as a general formula (I), a tautomer or a medicinal salt thereof:
wherein,
R 1 selected from phenyl or 5-6 membered heteroaryl, said phenyl or 5-6 membered heteroaryl being unsubstituted or substituted by 1,2 or 3 substituents R 3 The substitution is carried out on the raw materials,
R 3 is selected from C 1-6 Alkyl, - (C) 1-4 Alkylene radical) 0-1 -Cyc、-O-(C 1-4 Alkylene radical) 0-1 -Cyc、-S-(C 1-4 Alkylene radical) 0-1 -Cyc、-NH-(C 1-4 Alkylene radical) 0-1 -Cyc、-NH-C 1-6 Alkyl, -N (C) 1-6 Alkyl radical) 2 、-O-C 1-6 Alkyl or-S-C 1-6 Alkyl radical, R 3 Optionally unsubstituted or further substituted by one or more R 4 Substituted by a substituent;
cyc is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl or 5-to 10-membered heteroaryl, said C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl or 5-to 10-membered heteroaryl unsubstituted or substituted by 1,2 or 3 substituents R 5 Substituted;
R 4 or R 5 Each of which isIndependently selected from H, hydroxy, amino, halogen, cyano, nitro, -OR a 、-SR a 、＝O、＝S、-C(O)R a 、-C(S)R a 、-C(O)OR a 、-C(S)OR a 、-C(O)N(R a ) 2 、-N(R a ) 2 、-S(O) 2 R a 、-O-S(O 2 )OR a 、-O-S(O) 2 R a Or R a Said R is a Each independently selected from H, C 1-6 Alkyl or C 3-6 Cycloalkyl radical, R a Unsubstituted or further substituted by one or more groups selected from halogen, hydroxy, C 1-3 Alkyl or cyano;
R 2 selected from hydrogen, halogen, cyano, C 1-3 Alkyl radical, C 1-3 Alkoxy radical, C 2-4 Alkenyl, halo C 2-4 Alkenyl or C 2-4 Alkynyl.
In some embodiments, R in formula (I) 1 Selected from phenyl or 5-6 membered heteroaryl, optionally containing 1 or 2 heteroatoms each independently selected from N, O or S, and said heteroaryl ring group is unsubstituted or substituted with 1,2 or 3 substituents R 3 Substituted; preferably R 1 Is selected from
The R is 1 Unsubstituted or substituted by 1,2 or 3 substituents R 3 And (4) substituting.
In some embodiments, R in formula (I) 3 Is substituted in meta position.
In some embodiments, R in formula (I) 3 Is selected from C 1-6 Alkyl, -C 1-3 Alkylene-phenyl, -C 1-3 alkylene-C 3-6 Cycloalkyl or-C 1-3 Alkylene- (5-to 10-membered heteroaryl), said R 3 Optionally selected from H, cyano, halogen, hydroxy, amino, C 1-3 Alkyl radical, C 1-3 Hydroxyalkyl radical, C 1-3 Haloalkyl, C 1-3 Alkoxy radical, C 1-3 Haloalkoxy, -C (= O) O-C 1-3 Alkyl or-S (= O) 2 -C 1-3 Alkyl substituent; preferably R 3 Is selected from C 1-6 Alkyl, aryl, heteroaryl, and heteroaryl,
The R is 3 Optionally substituted by a group selected from H, cyano, halogen, hydroxy, amino, C 1-3 Alkyl radical, C 1-3 Hydroxyalkyl radical, C 1-3 Haloalkyl, C 1-3 Alkoxy radical, C 1-3 Haloalkoxy, -C (= O) O-C 1-3 Alkyl or-S (= O) 2 -C 1-3 Alkyl substituents.
In some embodiments, R in formula (I) 2 Selected from halogen, C 1-3 Alkyl or C 1-3 An alkoxy group; preferably chlorine, methyl or methoxy.
In some embodiments, the compound of formula (I) is selected from compounds represented by general formula (IA):
wherein,
X 1 is selected from N or CH;
X 2 is selected from N orCH；
R 3 Is selected from C 1-6 Alkyl, - (C) 1-4 Alkylene radical) 0-1 -Cyc、-O-(C 1-4 Alkylene radical) 0-1 -Cyc、-S-(C 1-4 Alkylene radical) 0-1 -Cyc、-NH-(C 1-4 Alkylene radical) 0-1 -Cyc、-NH-C 1-6 Alkyl, -N (C) 1-6 Alkyl radical) 2 、-O-C 1-6 Alkyl or-S-C 1-6 Alkyl radical, R 3 Optionally unsubstituted or further substituted by one or more R 4 Substituted by a substituent;
cyc is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl or 5-to 10-membered heteroaryl, said C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl or 5-to 10-membered heteroaryl unsubstituted or substituted by 1,2 or 3 substituents R 5 Substituted;
R 4 or R 5 Each independently selected from H, hydroxy, amino, halogen, cyano, nitro, -OR a 、-SR a 、＝O、＝S、-C(O)R a 、-C(S)R a 、-C(O)OR a 、-C(S)OR a 、-C(O)N(R a ) 2 、-N(R a ) 2 、-S(O) 2 R a 、-O-S(O 2 )OR a 、-O-S(O) 2 R a Or R a Said R is a Each independently selected from H, C 1-6 Alkyl or C 3-6 Cycloalkyl radical, R a Unsubstituted or further substituted by one or more groups selected from halogen, hydroxy, C 1-3 Alkyl or cyano;
R 2 selected from hydrogen, halogen, cyano, C 1-3 Alkyl radical, C 1-3 Alkoxy radical, C 2-4 Alkenyl, halo C 2-4 Alkenyl or C 2-4 Alkynyl.
In some embodiments, formula (I) is selected from:
in some embodiments, the method of synthesizing formula (I) comprises:
reacting the compound of the general formula (II) under an acidic condition to obtain a compound of the general formula (I),
wherein R is 1 And R 2 The definition of (A) is as described in formula (I).
The invention also provides a pharmaceutical composition, which is characterized by comprising at least one compound shown as the formula (I) in a therapeutically effective amount and at least one pharmaceutically acceptable auxiliary material.
The invention further provides a pharmaceutical composition, which is characterized in that the mass percentage of the therapeutically effective amount of at least one compound shown in the formula (I) and pharmaceutically acceptable auxiliary materials is 0.0001.
The invention provides application of a compound or a pharmaceutical composition shown in a structural formula (I) in preparation of a medicament.
The invention further provides a preferable technical scheme of the application:
preferably, the application is the application in preparing a medicament for treating and/or preventing cancer.
Preferably, the cancer is selected from breast cancer, multiple myeloma, bladder cancer, endometrial cancer, gastric cancer, cervical cancer, rhabdomyosarcoma, non-small cell lung cancer, pleomorphic lung cancer, ovarian cancer, esophageal cancer, melanoma, colorectal cancer, hepatoma, head and neck tumors, hepatobiliary cell carcinoma, myelodysplastic syndrome, glioblastoma, prostate cancer, thyroid cancer, xu Wangshi cell tumor, lung squamous cell carcinoma, lichenification keratosis, synovial sarcoma, skin cancer, pancreatic cancer, testicular cancer, or liposarcoma.
The invention also provides a method for treating and/or preventing diseases, which comprises the step of administering at least one compound shown in the structural formula (I) or a pharmaceutical composition containing the compound to a treated object in a therapeutically effective amount.
The present invention also provides a method for treating cancer, comprising administering to a subject a therapeutically effective amount of at least any one of the compounds of formula (I) or a pharmaceutical composition comprising the same.
Preferably, in the above method, the cancer is selected from breast cancer, multiple myeloma, bladder cancer, endometrial cancer, gastric cancer, cervical cancer, rhabdomyosarcoma, non-small cell lung cancer, pleomorphic lung cancer, ovarian cancer, esophageal cancer, melanoma, colorectal cancer, hepatoma, head and neck tumors, hepatobiliary cell carcinoma, myelodysplastic syndrome, glioblastoma, prostate cancer, thyroid cancer, xu Wangshi cell tumor, lung squamous cell carcinoma, lichenification keratosis, synovial sarcoma, skin cancer, pancreatic cancer, testicular cancer, or liposarcoma.
Unless otherwise indicated, general chemical terms used in the structural formulae have the usual meanings.
For example, the term "halogen" as used herein, unless otherwise specified, refers to fluorine, chlorine, bromine or iodine.
In the present invention, unless otherwise specified, "alkyl" includes straight or branched chain monovalent saturated hydrocarbon groups. For example, alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 3- (2-methyl) butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-methylpentyl and the like. Similarly, "radical 1-8 Alkyl group "of" 1-8 By "meansGroups comprising 1,2,3,4, 5, 6, 7 or 8 carbon atoms arranged in a straight or branched chain.
“C 1-3 Alkylene "refers to a straight or branched chain divalent saturated hydrocarbon group. Such as methylene, 1,2-ethylene, 1,3-propylene or 1,2-isopropylene.
“C 2-6 Alkenyl "or" C 2-6 Alkynyl "refers to a straight or branched chain unsaturated hydrocarbon group.
"alkoxy" refers to the oxygen ether form of the straight or branched chain alkyl group previously described, i.e., -O-alkyl.
In the present invention, "a", "an", "the", "at least one" and "one or more" are used interchangeably. Thus, for example, a composition that includes "a" pharmaceutically acceptable excipient may be interpreted to mean that the composition includes "one or more" pharmaceutically acceptable excipients.
The term "aryl", as used herein, unless otherwise indicated, refers to an unsubstituted or substituted monocyclic or fused ring aromatic group comprising carbocyclic atoms. Preferably, aryl is a 6 to 10 membered monocyclic or bicyclic aromatic ring group. Preferably phenyl or naphthyl. Most preferred is phenyl. The aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl group, wherein the ring attached to the parent structure is an aryl ring, non-limiting examples include, but are not limited to, benzocyclopentyl.
The term "heterocyclyl", as used herein, unless otherwise specified, refers to an unsubstituted or substituted stabilizing ring system of carbon atoms and 1-3 heteroatoms selected from N, O or S, which is a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent comprising from 3 to 20 carbon atoms in which the nitrogen or sulfur heteroatom may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heterocyclic group may be attached to any heteroatom or carbon atom to form a stable structure. Examples of such heterocyclyl groups include, but are not limited to, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, and tetrahydrooxadiazolyl.
The term "heteroaryl", in the present invention, unless otherwise indicated, refers to an unsubstituted or substituted stable 5-or 6-membered monocyclic aromatic ring system or an unsubstituted or substituted 9-or 10-membered benzo-fused heteroaromatic ring system or bicyclic heteroaromatic ring system, consisting of carbon atoms and 1 to 4 heteroatoms selected from N, O or S, and wherein said nitrogen or sulfur heteroatoms may be optionally oxidized and said nitrogen heteroatoms may be optionally quaternized. The heteroaryl group may be attached at any heteroatom or carbon atom to form a stable structure. Examples of heteroaryl groups include, but are not limited to, thienyl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl adenine, quinolinyl, or isoquinolinyl. The heteroaryl group can be fused to an aryl, heterocyclyl, or cycloalkyl ring, wherein the ring attached to the parent structure is a heteroaryl ring.
The term "cycloalkyl" refers to a cyclic saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent having 3 to 10 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
The term "substituted" means that one or more hydrogen atoms in a group are replaced by the same or different substituents, respectively. Typical substituents include, but are not limited to, halogen (F, cl, br or I), C 1-8 Alkyl radical, C 3-12 Cycloalkyl, -OR 1 、-SR 1 、＝O、＝S、-C(O)R 1 、-C(S)R 1 、＝NR 1 、-C(O)OR 1 、-C(S)OR 1 、-NR 1 R 2 、-C(O)NR 1 R 2 Cyano, nitro, -S (O) 2 R 1 、-O-S(O 2 )OR 1 、-O-S(O) 2 R 1 、-OP(O)(OR 1 )(OR 2 ) (ii) a Wherein R is 1 And R 2 Independently selected from-H, C 1-6 Alkyl radical, C 1-6 A haloalkyl group. In some embodiments, the substituents are independently selected from the group consisting of-F, -Cl, -Br, -I, -OH, trifluoromethoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, -SCH 3 、-SC 2 H 5 Formaldehyde group, -C (OCH) 3 ) Cyano, nitro, -CF 3 、-OCF 3 Amino, dimethylamino, methylthio, sulfonyl and acetyl groups.
Examples of substituted alkyl groups include, but are not limited to, 2,3-dihydroxypropyl, 2-aminoethyl, 2-hydroxyethyl, pentachloroethyl, trifluoromethyl, methoxymethyl, pentafluoroethyl, phenylmethyl, dioxolanylmethyl, and piperazinylmethyl.
Examples of substituted alkoxy groups include, but are not limited to, 2-hydroxyethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2-methoxyethoxy, 2-aminoethoxy, 2,3-dihydroxypropoxy, cyclopropylmethoxy, aminomethoxy, trifluoromethoxy, 2-diethylaminoethoxy, 2-ethoxycarbonylethoxy, 3-hydroxypropoxy.
The term "pharmaceutically acceptable salt" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
Since the compounds of formula (I) are intended for pharmaceutical use, it is preferred to use them in a certain purity, for example, at least 60% pure, more suitably at least 75% pure, and especially at least 98% pure (% by weight).
Prodrugs of the compounds of the invention are included within the scope of the invention. In general, the prodrug refers to a functional derivative that is readily converted in vivo to the desired compound. For example, any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of the present application, which upon administration to a subject is capable of providing, directly or indirectly, a compound of the present application or a pharmaceutically active metabolite or residue thereof.
The compounds of the present invention may contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention includes all possible diastereomers and racemic mixtures thereof, substantially pure resolved enantiomers thereof, all possible geometric isomers thereof, and pharmaceutically acceptable salts thereof.
Certain therapeutic advantages may be provided when compounds of formula (I) are replaced with heavier isotopes such as deuterium, for example, which may be attributed to greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
When solvates or polymorphs exist of the compounds of formula (I) and pharmaceutically acceptable salts thereof, the present invention includes any possible solvates and polymorphs. The type of solvent for forming the solvate is not particularly limited as long as the solvent is pharmaceutically acceptable. For example, water, ethanol, propanol, acetone, and the like can be used.
The term "composition," as used herein, is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. Accordingly, pharmaceutical compositions containing the compounds of the invention as active ingredients as well as methods for preparing the compounds of the invention are also part of the invention. In addition, some crystalline forms of the compounds may exist as polymorphs and as such are included in the present invention. In addition, some compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates also fall within the scope of the present invention.
The pharmaceutical composition provided by the invention comprises a compound shown in formula (I) (or pharmaceutically acceptable salt thereof) as an active component, a pharmaceutically acceptable excipient and other optional therapeutic components or auxiliary materials.
In order to make the above clear and definite, the present invention will be further illustrated by the following examples. The following examples are intended only to illustrate specific embodiments of the present invention so as to enable those skilled in the art to understand the present invention, but not to limit the scope of the present invention. In the embodiments of the present invention, technical means or methods not specifically described are conventional in the art.
All parts and percentages herein are by weight and all temperatures are in degrees Celsius, unless otherwise indicated.
The synthesis scheme is as follows:
reacting the compound of the general formula (II) under an acidic condition to obtain the compound of the general formula (I).
Preparation of intermediate Compound M1
The method comprises the following steps:
4,6-dichloro-3-methylpyridazine (1.3 g), 2,4-dimethoxy-5-pyrimidineboronic acid (1.6 g), pd (dppf) Cl 2 -CH 2 Cl 2 (325.64 mg) and Cs 2 CO 3 (3.75 g) was mixed with dioxane (25 mL) and water (5 mL) and the mixture was heated to 70 ℃ under nitrogen. After 2h, TLC monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography purification (PE: EA = 1:1) to obtain 1.1g white solid, i.e. compound M1 (M + H) + :267、269)。
Preparation of intermediate compound M2
Step 1:
3-amino-4-bromo-6-chloropyridazine (2 g), 3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1- (triisopropylsilyl) -1H-pyrrole (1.6 g), pd (dppf) Cl 2 -CH 2 Cl 2 (289.45 mg) and K 2 CO 3 (2.20 g) was mixed with dioxane (25 mL) and water (5 mL), and the mixture was heated to 70 ℃ under nitrogen atmosphere to react. After 2h, TLC monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography purification (DCM: meOH = 30) + :352、354)。
Step 2
The compound M2-1 (3.1 g), 2,4-dimethoxy-5-pyrimidineboronic acid (3.25 g), pd (dppf) Cl 2 -CH 2 Cl 2 (341.28 mg) and Cs 2 CO 3 (8.69 g) was mixed with dioxane (50 mL) and water (10 mL), and the mixture was heated to 90 ℃ under nitrogen atmosphere to react. After 12h, TLC monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography purification (DCM: meOH = 20) + :299)。
Step 3
Compound M2-2 (1.1 g) and cuprous chloride (730.83 mg) were mixed in acetonitrile (50 mL), tert-butyl nitrite was added dropwise, and the temperature was raised to 70 ℃ under nitrogen protection to react. After 2h, TLC monitoring indicated complete reaction. Filtering the reaction solution with diatomaceous earth, washing the filter cake with ethyl acetate, and purifying the filtrate by column chromatography (PE: EA = 1:5) to obtain 212mg of yellow solid, i.e., compound M2 (M + H) + :318,320)。
Example 1: synthesis of Compound 1 (4- ((5- (6- (2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl) -3-methylpyridazin-4-yl) -1H-pyrazol-1-yl) methyl) benzonitrile)
Step 1: synthesis of Compound 1-1
The compound 1H-pyrazole-3-boronic acid pinacol ester (109 mg), p-cyanobenzyl bromide (100 mg) and K 2 CO 3 (211 mg) was mixed with acetonitrile (5 mL), and the mixture was heated to 70 ℃ to react overnight. LCMS monitoring indicated complete reaction. Directly evaporating the reaction solution to dryness to obtain white viscous substance 100mg, i.e. compound 1-1 (M + H) + :228)。
Step 2: synthesis of Compound 1-2
Compounds M1 (129 mg), 1-1 (100 mg), K 2 CO 3 (152mg)、Pd(dppf)Cl 2 -CH 2 Cl 2 (36 mg) was mixed with dioxane (5 mL) and water (1 mL), and the mixture was heated to 70 ℃ under nitrogen atmosphere to react. After 4h, LCMS monitoring indicated complete reaction. The reaction solution was directly evaporated to dryness. Separating and purifying by column chromatography (PE: EA = 1:1) to obtain 70mg of white solid, i.e. compound 1-2 (M + H) + :413)。
And step 3: synthesis of Compound 1
Compound 1-2 (70 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping acetonitrile to obtain 50mg white solid, i.e. compound 1 (M + H) + :386)。
Example 2: synthesis of Compound 2 (4- ((3- (6- (2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl) -3-methylpyridazin-4-yl) -1H-pyrazol-1-yl) methyl) benzonitrile)
Step 1: synthesis of Compound 2-1
The compound 1H-pyrazole-3-boronic acid pinacol ester (109 mg), p-cyanobenzyl bromide (100 mg) and K 2 CO 3 (211 mg) was mixed with acetonitrile (5 mL), and the mixture was heated to 70 ℃ to react overnight. LCMS monitoring indicated complete reaction. Direct steaming of reaction liquidDrying to obtain white viscous substance 100mg, i.e. compound 2-1 (M + H) + :228)。
Step 2: synthesis of Compound 2-2
Compounds M1 (129 mg), 2-1 (100 mg), K 2 CO 3 (152mg)、Pd(dppf)Cl 2 -CH 2 Cl 2 (36 mg) was mixed with dioxane (5 mL) and water (1 mL), and the mixture was heated to 70 ℃ under nitrogen atmosphere to react. After 4h, TLC monitoring indicated complete reaction. The reaction solution was directly evaporated to dryness. Separating and purifying by column chromatography (PE: EA = 1:1) to obtain 60mg of white solid, i.e. compound 2-2 (M + H) + :413)。
And step 3: synthesis of Compound 2
Compound 2-2 (60 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping acetonitrile to obtain 40mg white solid, i.e. compound 2 (M + H) + :386)。
Example 3: synthesis of Compound 3 (5- (6-methyl-5- (1- (4-methylbenzyl) -1H-pyrazol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 3-1
The compound 1H-pyrazole-3-boronic acid pinacol ester (109 mg), p-methylbenzyl bromide (100 mg) and K 2 CO 3 (211 mg) was mixed with acetonitrile (5 mL), and the mixture was heated to 70 ℃ to react overnight. LCMS monitoring indicated complete reaction. Directly evaporating the reaction solution to dryness to obtain white viscous substance 100mg, i.e. compound 3-1 (M + H) + :217)。
Step 2: synthesis of Compound 3-2
Mixing compound M1 (129 mg), 3-1 (100 mg), and K 2 CO 3 (152mg)、Pd(dppf)Cl 2 -CH 2 Cl 2 (36 mg) was mixed with dioxane (5 mL) and water (1 mL) and the mixture was heated to 70 ℃ under nitrogen atmosphere for reaction overnight.The reaction solution was directly evaporated to dryness. Separating and purifying by column chromatography (PE: EA = 1:1) to obtain 70mg of white solid, i.e. compound 3-2 (M + H) + :403)。
And step 3: synthesis of Compound 3
Compound 3-2 (70 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping acetonitrile to obtain 50mg white solid, i.e. compound 3 (M + H) + :375)。
Example 4: synthesis of Compound 4 (5- (5- (1-benzyl-1H-pyrazol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 4-1
The compound 1H-pyrazole-3-boronic acid pinacol ester (109 mg), bromobenzyl (95 mg) and K 2 CO 3 (211 mg) was mixed with acetonitrile (5 mL), and the mixture was heated to 70 ℃ to react overnight. TLC monitoring indicated complete reaction. Directly evaporating the reaction solution to dryness to obtain white viscous substance 100mg, i.e. compound 4-1 (M + H) + :203)。
Step 2: synthesis of Compound 4-2
Mixing compound M1 (129 mg), 4-1 (100 mg), and K 2 CO 3 (152mg)、Pd(dppf)Cl 2 -CH 2 Cl 2 (36 mg) was mixed with dioxane (5 mL) and water (1 mL), and the mixture was heated to 70 ℃ under nitrogen atmosphere to react. After 2h, TLC monitoring indicated complete reaction. The reaction solution was directly evaporated to dryness. Separating and purifying by column chromatography (PE: EA = 1:1) to obtain 70mg of white solid, i.e. compound 4-2 (M + H) + :389)。
And step 3: synthesis of Compound 4
Compound 4-2 (70 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping acetonitrile to obtain 50mg white solid, i.e. compound 4 (M + H) + :361)。
Example 5: synthesis of Compound 5 (5- (5- (1- (4-chlorobenzyl) -1H-pyrazol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 5-1
Mixing compound M1 (70 mg), 1H-pyrazole-3-boronic acid pinacol ester (76.40 mg) and K 2 CO 3 (72.55mg)、Pd(dppf)Cl 2 -CH 2 Cl 2 (10.72 mg) was mixed with dioxane (2 mL) and water (0.4 mL), and the mixture was heated to 70 ℃ under nitrogen atmosphere to react. After 2h, TLC monitoring showed the reaction was complete. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Pulping dichloromethane/petroleum ether (V: V = 1/1) to obtain 70mg white solid, i.e. compound 5-1 (M + H) + :299)。
Step 2: synthesis of Compound 5-2
Compound 5-1 (70 mg), benzyl p-chlorobromide (50.60 mg) and K 2 CO 3 (64.86 mg) was mixed with DMF (2 mL) and the mixture was heated to 50 ℃ for reaction. After 1h, TLC monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Pulping acetonitrile to obtain 70mg of white solid, i.e. compound 5-2 (M + H) + :423、425)。
And step 3: synthesis of Compound 5
Compound 5-2 (90 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping acetonitrile to obtain 63mg of white solid, i.e. compound 5 (M + H) + :395、397)。
Example 6: synthesis of Compound 6 (5- (6-methyl-5- (1-methyl-1H-pyrazol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 6-1
Compound M1 (70 mg), 1-methyl-3-pyrazoleboronic acid pinacol ester (76.40 mg), K 2 CO 3 (72.55mg)、Pd(dppf)Cl 2 -CH 2 Cl 2 (10.72 mg) was mixed with dioxane (2 mL) and water (0.4 mL), and the mixture was heated to 70 ℃ under nitrogen atmosphere to react. After 2h, TLC monitoring indicated complete reaction. The reaction solution was directly evaporated to dryness. Separating and purifying by column chromatography (PE: EA = 1:1) to obtain 70mg of white solid, i.e. compound 6-1 (M + H) + :313)。
Step 2: synthesis of Compound 6
Compound 6-1 (70 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping acetonitrile to obtain 50mg white solid, i.e. compound 6 (M + H) + :285)。
Example 7: synthesis of Compound 7 (5- (5- (1-isopropyl-1H-pyrazol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 7-1
Compound M1 (70 mg), 1-isopropyl-3-pyrazoleboronic acid pinacol ester (77.40 mg), K 2 CO 3 (72.55mg)、Pd(dppf)Cl 2 -CH 2 Cl 2 (10.72 mg) was mixed with dioxane (2 mL) and water (0.4 mL), and the mixture was heated to 70 ℃ under nitrogen atmosphere to react. After 2h, TLC monitoring indicated complete reaction. The reaction solution was directly evaporated to dryness. Column chromatography separation and purification (PE: EA = 1:1) to obtain 70mg of white solid, namely compound 7-1 (M + H) + :341)。
Step 2: synthesis of Compound 7
Compound 7-1 (70 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping acetonitrile to obtain 50mg white solid, i.e. compound 7 (M + H) + :313)。
Example 8: synthesis of Compound 8 (5- (5- (1- (cyclopropylmethyl) -1H-pyrazol-4-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 8-1
Compound M1 (70 mg), 4-pyrazoleboronic acid pinacol ester (76.40 mg), and K 2 CO 3 (72.55mg)、Pd(dppf)Cl 2 -CH 2 Cl 2 (10.72 mg) was mixed with dioxane (2 mL) and water (0.4 mL), and the mixture was heated to 70 ℃ under nitrogen atmosphere to react. After 2h, TLC monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Pulping dichloromethane/petroleum ether (V: V = 1:1) to obtain 70mg white solid, i.e. compound 8-1 (M + H) + :299)。
Step 2: synthesis of Compound 8-2
Compound 8-1 (70 mg), bromomethylcyclopropane (30.10 mg) and K 2 CO 3 (64.86 mg) was mixed with DMF (2 mL) and the mixture was heated to 50 ℃ for reaction. After 1h, TLC monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Pulping acetonitrile to obtain 60mg of white solid, i.e. compound 8-2 (M + H) + :353)。
And step 3: synthesis of Compound 8
Compound 8-2 (60 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping acetonitrile to obtain 50mg white solid, i.e. compound 8 (M + H) + :325)。
Example 9: synthesis of Compound 9 (5- (5- (1- (4-chlorobenzyl) -1H-pyrazol-4-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 9-1
Compound 8-1 (70 mg), p-chlorobenzyl bromide (50.30 mg) and K 2 CO 3 (64.86 mg) was mixed with DMF (2 mL) and the mixture was heated to 50 ℃ for reaction. After 1h, TLC monitoring showed the reaction was complete. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Pulping acetonitrile to obtain 75mg of white solid, i.e. compound 9-1 (M + H) + :423)。
Step 2: synthesis of Compound 9
Compound 9-1 (75 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping acetonitrile to obtain 50mg white solid, i.e. compound 9 (M + H) + :395)。
Example 10: synthesis of Compound 10 (4- ((4- (6- (2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl) -3-methylpyridazin-4-yl) -1H-pyrazol-1-yl) methyl) benzonitrile)
Step 1: synthesis of Compound 10-1
Compound 8-1 (70 mg), p-cyanobenzyl bromide (50.60 mg) and K 2 CO 3 (64.86 mg) was mixed with DMF (2 mL) and the mixture was heated to 50 ℃ for reaction. After 1h, TLC monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Pulping acetonitrile to obtain 90mg of white solid, i.e. compound 10-1(M+H + :414)。
And 3, step 3: synthesis of Compound 10
Compound 10-1 (90 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping with acetonitrile to obtain 50mg white solid, i.e. compound 10 (M + H) + :386)。
Example 11: synthesis of Compound 11 (5- (5- (furan-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 11-1
Compound M1 (100 mg), 3-furanboronic acid (84 mg), and K 2 CO 3 (77.74mg)、Pd(dppf)Cl 2 -CH 2 Cl 2 (21.95 mg) was mixed with dioxane (4 mL) and water (1 mL), and the mixture was heated to 70 ℃ under nitrogen atmosphere to react. After 1h, TLC monitoring indicated complete reaction. Pouring the reaction solution into appropriate amount of water, mixing, extracting with ethyl acetate for three times, washing with saturated saline solution, drying, mixing with silica gel, separating by column chromatography, and pulping with petroleum ether/ethyl acetate (V: V = 5:1-1:3) as eluent to obtain 80mg yellow solid, i.e. compound 11-1 (M + H) + :299)。
Step 2: synthesis of Compound 11
Compound 11-1 (80 mg) was mixed with 1M dilute hydrochloric acid solution (3 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping acetonitrile to obtain 26mg white solid, i.e. compound 11 (M + H) + :271)。
Example 12: synthesis of Compound 12 (5- (6-methyl-5- (1H-pyrrol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 16-1
Compound M1 (70 mg), 3- (tetramethyl-1,3,2-dioxaborolan-2-yl) -1- [ tris (propan-2-yl) silyl]-1H-pyrrole (157.22 mg), K 2 CO 3 (103.65 mg) and Pd (dppf) Cl 2 -CH 2 Cl 2 (12.25 mg) was mixed with dioxane (2.5 mL) and water (0.5 mL), and the mixture was heated to 70 ℃ under nitrogen atmosphere to react. After 2h, TLC monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline, drying, and concentrating to obtain brown solid (136 mg), namely the compound 16-1 (M + H) + 298, 454). Used in the next step without purification.
Step 2: synthesis of Compound 16-2
Compound 16-1 (136 mg) and tetrabutylammonium fluoride (224.78 mg) were mixed in THF (5 mL) and stirred at room temperature. After 0.5h, TLC monitoring indicated complete reaction. Pouring the reaction solution into appropriate amount of water, mixing, extracting with ethyl acetate for three times, washing with saturated saline, drying, and concentrating to obtain brown solid (90 mg), i.e. compound 16-2 (M + H) + :298). Used in the next step without purification.
And step 3: synthesis of Compound 12
Compound 16-2 (30 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping DMF/methanol (V: V = 1/2) to obtain 11.8mg light green solid, i.e. compound 12 (M + H) + :270)。
Example 13: synthesis of Compound 13 (5- (5- (1- (cyclopropylmethyl) -1H-pyrrol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 13-1
Compound 16-2 (59 mg) and bromomethylcyclopropane (40.1)9mg)、Cs 2 CO 3 (129.31 mg) was mixed with DMF (6 mL) and the mixture was heated to 50 ℃ for reaction. After 10h, TLC monitoring indicated complete reaction. The reaction solution was poured into an appropriate amount of water and mixed well, extracted three times with ethyl acetate, washed with saturated brine, dried and concentrated to give yellow oil (65 mg), i.e., compound 13-1 (M + H) + :352). Used in the next step without purification.
And 2, step: synthesis of Compound 13
Compound 13-1 (90 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. The reaction was spun dry to give crude and preparative TLC purification (DCM/MeOH = 10/1) afforded 36.9mg of a yellow solid, compound 13 (M + H) + :324)。
Example 14: synthesis of Compound 14 (5- (5- (1- (4-chlorobenzyl) -1H-pyrrol-3-yl) -6-methylpyridin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 14-1
Compound 16-2 (59 mg), benzyl p-chlorobromide (61.16 mg) and Cs 2 CO 3 (129.31 mg) was mixed with DMF (6 mL) and the mixture was heated to 50 ℃ for reaction. After 1.5h, TLC monitoring indicated complete reaction. Mixing the reaction solution with appropriate amount of water, extracting with ethyl acetate for three times, washing with saturated saline, drying, and concentrating to obtain yellow solid (80 mg), i.e. compound 14-1 (M + H) + 421, 423). Used in the next step without purification.
Step 2: synthesis of Compound 14
Compound 14-1 (80 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping with DCM/MeOH (1/1) to obtain 7.6mg of light yellow solid, i.e. compound 14 (M + H) + :394、396)。
Example 15: synthesis of Compound 15 (5- (5- (1- (4-methoxybenzyl) -1H-pyrrol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 15-1
Mixing compound 16-2 (59 mg), p-methoxybenzyl chloride (59.85 mg) and Cs 2 CO 3 (129.31 mg) was mixed with DMF (6 mL) and the mixture was heated to 50 ℃ for reaction. After 1.5h, TLC monitoring indicated complete reaction. Mixing the reaction solution with appropriate amount of water, extracting with ethyl acetate for three times, washing with saturated saline, drying, and concentrating to obtain yellow solid (80 mg), i.e. compound 15-1 (M + H) + :418). Used in the next step without purification.
Step 2: synthesis of Compound 15
Compound 15-1 (80mg, 191.64umol) was mixed with 1M dilute hydrochloric acid solution (2 mL) and the mixture was heated to 70 ℃ for reaction. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, separating the prepared liquid phase to obtain 12.3mg white solid, i.e. compound 15 (M + H) + :390)。
Example 16: synthesis of Compound 16 (4- ((3- (6- (2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl) -3-methylpyridazin-4-yl) -1H-pyrrol-1-yl) methyl) benzonitrile)
The method comprises the following steps: synthesis of Compound 16-3
Compound 16-2 (60 mg), p-cyanobenzyl bromide (47.48 mg) and K 2 CO 3 (55.78 mg) was mixed with DMF (2 mL) and the mixture was heated to 50 ℃ for reaction. After 10h, TLC monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Preparative TLC purification (PE/EA = 3/1) yielded 60mg of a yellow solid, compound 16-3 (M + H) + :413)。
And 4, step 4: synthesis of Compound 16
Compound 16-3 (60 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. The crude product was spin-dried to prepare a liquid phase and 3.2mg of a yellow solid, compound 16 (M + H) + :385)。
Example 17: synthesis of Compound 17 (5- (5- (1-benzyl-1H-pyrrol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 17-1
Mixing compound 16-2 (60 mg), benzyl bromide (46.48 mg) and Cs 2 CO 3 (131.72 mg) was mixed with DMF (2 mL) and the mixture was heated to 50 ℃ for reaction. After 3h, LCMS monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography separation and purification (DCM: meOH = 15) + :388)。
And 4, step 4: synthesis of Compound 17
Compound 17-2 (60mg, 145.47umol) was mixed with 1M dilute hydrochloric acid solution (2 mL) and reacted at an elevated temperature to 70 ℃. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping with ethanol to obtain 30mg white solid, i.e. compound 17 (M + H) + :360)。
1 H-NMR(500MHz,DMSO-d 6 )δ11.50-11.37(m,2H),8.28(d,J＝5.9Hz,1H),8.22(s,1H),7.49(s,1H),7.38-7.35(m,2H),7.31-7.28(m,3H),7.03(s,1H),6.52(s,1H),5.21(s,2H),2.76(s,3H).
Example 18: synthesis of Compound 18 (5- (5- (1- (3-methoxybenzyl) -1H-pyrrol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 18-1
Mixing compound 16-2 (20 mg), m-methoxybenzyl bromide (41 mg) and Cs 2 CO 3 (66.2 mg) was mixed with DMF (2 mL), and the mixture was heated to 50 ℃ to react. After 3h, LCMS monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography separation and purification (DCM: meOH = 15) + :418)。
Step 2: synthesis of Compound 18
Compound 18-2 (11 mg) was mixed with 1M dilute hydrochloric acid solution (1.5 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping with ethanol to obtain 4.2mg yellow solid, i.e. compound 18 (M + H) + :390)。
Example 19: synthesis of Compound 19 (5- (6-methyl-5- (1- (3- (trifluoromethyl) benzyl) -1H-pyrrol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 19-1
Mixing compound 16-2 (50 mg), 1-chloromethyl-3-trifluoromethylbenzene (118 mgl) and Cs 2 CO 3 (198 mg) was mixed with DMF (4 mL) and the mixture was heated to 50 ℃ for reaction. After 3h, LCMS monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography purification (DCM: meOH = 15) + :456)。
Step 2: synthesis of Compound 19
Compound 19-2 (60 mg) was mixed with 1M dilute hydrochloric acid solution (5 mL), and the mixture was heated to 70 ℃ to react. After the reaction time of 5 hours,LCMS monitoring showed reaction completion. Filtering to obtain crude product, pulping with ethanol to obtain 41.48mg yellow solid, i.e. compound 19 (M + H) + :428)。
Example 20: synthesis of Compound 20 (5- (6-methyl-5- (1- (2- (trifluoromethyl) benzyl) -1H-pyrrol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 20-1
Compound 16-2 (50 mg), 2-trifluoromethylbenzyl chloride (118 mg) and Cs 2 CO 3 (198 mg) was mixed with DMF (4 mL) and the mixture was heated to 50 ℃ for reaction. After 3h, LCMS monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography purification (DCM: meOH = 15) + :456)。
Step 2: synthesis of Compound 20
Compound 20-1 (50 mg) was mixed with 1M dilute hydrochloric acid solution (5 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping with ethanol to obtain 32.83mg yellow solid, i.e. compound 20 (M + H) + :428)。
Example 21: synthesis of Compound 21 (5- (6-methyl-5- (1- (quinolin-4-ylmethyl) -1H-pyrrol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 21-1
Compound 16-2 (40 mg), 4-chloromethylquinoline (56.97 mg) and Cs 2 CO 3 (159 mg) was mixed with DMF (3 mL), and the mixture was heated to 50 ℃ for reaction. After 3h, LCMS monitoring indicated complete reaction. Inverse directionPouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography separation and purification (DCM: meOH = 15) + :439)。
Step 2: synthesis of Compound 21
Compound 21-1 (30 mg) was mixed with 1M dilute hydrochloric acid solution (3 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping with ethanol to obtain 18.35mg yellow solid, i.e. compound 21 (M + H) + :411)。
Example 22: synthesis of Compound 22 (5- (6-methyl-5- (1- (1-phenylethyl) -1H-pyrrol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 22-1
Compound 16-2 (30 mg), 1-chloro-1-phenylethane (51.1 mg) and Cs 2 CO 3 (119 mg) was mixed with DMF (2 mL), and the mixture was heated to 50 ℃ to react. After 3h, LCMS monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography separation and purification (DCM: meOH = 15) + :402)。
Step 2: synthesis of Compound 22
Compound 22-1 (20 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping with ethanol to obtain 8.3mg yellow solid, i.e. compound 22 (M + H) + :374)。
Example 23: synthesis of Compound 23 (5- (5- (1- (cyclopentylmethyl) -1H-pyrrol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 23-1
Compound 16-2 (30 mg), chloromethylcyclopentane (43.1 mg) and Cs 2 CO 3 (119 mg) was mixed with DMF (2 mL), and the mixture was heated to 50 ℃ to react. After 3h, LCMS monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography separation and purification (DCM: meOH = 15) + :380)。
Step 2: synthesis of Compound 23
Compound 23-1 (20 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping with ethanol to obtain 16.94mg yellow solid, i.e. compound 23 (M + H) + :352)。
Example 24: synthesis of Compound 24 (5- (5- (1- (cyclohexylmethyl) -1H-pyrrol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 24-1
Compound 16-2 (20 mg), chloromethylcyclohexane (28 mg) and Cs 2 CO 3 (66.2 mg) was mixed with DMF (2 mL), and the mixture was heated to 50 ℃ to react. After 3h, LCMS monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography separation and purification (DCM: meOH = 15) + :394)。
Step 2: synthesis of Compound 24
Compound 24-1 (10 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reactionAnd (4) completing. Filtering to obtain crude product, pulping with ethanol to obtain 5.92mg yellow solid, i.e. compound 24 (M + H) + :366)。
Example 25: synthesis of compound 25 (4- ((3- (6- (2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl) -3-methylpyridazin-4-yl) -1H-pyrrol-1-yl) methyl) -3-fluorobenzonitrile)
Step 1: synthesis of Compound 25-1
Compound 16-2 (20 mg), 4- (chloromethyl) -3-fluorobenzonitrile (36 mg) and Cs 2 CO 3 (66.2 mg) was mixed with DMF (2 mL), and the mixture was heated to 50 ℃ for reaction. After 3h, LCMS monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography separation and purification (DCM: meOH = 15) + :431)。
Step 2: synthesis of Compound 25
Compound 25-1 (20 mg) was mixed with 1M dilute hydrochloric acid solution (3 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping with ethanol to obtain 10.54mg yellow solid, i.e. compound 25 (M + H) + :403)。
Example 26: synthesis of Compound 26 (5- (5- (1- (2,4-difluorobenzyl) -1H-pyrrol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 26-1
The compounds 16-2 (100 mg), 2,4-difluorobenzyl chloride (113 mg) and Cs 2 CO 3 (228.7 mg) was mixed with DMF (5 mL) and the mixture was heated to 50 ℃ for reaction. After 3h, LCMS monitoring indicated complete reaction. Reaction solutionPouring into proper amount of water, mixing, extracting with ethyl acetate for three times, washing with saturated saline solution, drying, and concentrating to obtain crude product. Column chromatography separation and purification (DCM: meOH = 15) + :424)。
Step 2: synthesis of Compound 26
Compound 26-1 (80 mg) was mixed with 1M dilute hydrochloric acid solution (5 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping with ethanol to obtain 69.51mg yellow solid, i.e. compound 26 (M + H) + :396)。
Example 27: synthesis of Compound 27 (5- (6-methyl-5- (1- (pyridin-2-ylmethyl) -1H-pyrrol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 27-1
Compound 16-2 (40 mg), 2-chloromethylpyridine (35.58 mg) and Cs 2 CO 3 (91.50 mg) was mixed with DMF (3 mL) and the mixture was heated to 50 ℃ for reaction. After 3h, LCMS monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography separation and purification (DCM: meOH = 15) + :389)。
Step 2: synthesis of Compound 27
Compound 27-1 (30 mg) was mixed with 1M dilute hydrochloric acid solution (3 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping with ethanol to obtain 24.8mg yellow solid, i.e. compound 27 (M + H) + :361)。
Example 28: synthesis of Compound 28 (5- (6-methyl-5- (1- ((1-methyl-1H-pyrazol-3-yl) methyl) -1H-pyrrol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 28-1
The compound 16-2 (30 mg), 3- (chloromethyl) -1-methyl-1H-pyrazole (47.5 mg) and Cs 2 CO 3 (119 mg) was mixed with DMF (3 mL), and the mixture was heated to 50 ℃ to react. After 3h, LCMS monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography isolation and purification (DCM: meOH = 15) + :392)。
Step 2: synthesis of Compound 28
Compound 28-1 (25 mg) was mixed with 1M dilute hydrochloric acid solution (3 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping with ethanol to obtain 19.81mg yellow solid, i.e. compound 28 (M + H) + :364)。
Example 29: synthesis of Compound 29 (5- (5- (1- (4-ethoxybenzyl) -1H-pyrrol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 29-1
Compound 16-2 (20 mg), 1-chloromethyl-4-ethoxybenzene (36 mg) and Cs 2 CO 3 (66.2 mg) was mixed with DMF (2 mL), and the mixture was heated to 50 ℃ to react. After 3h, LCMS monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography separation and purification (DCM: meOH = 15) + :432)。
Step 2: synthesis of Compound 29
Compound 29-1 (20 mg) was mixed with 1M dilute hydrochloric acid solution (3 mL), and the temperature was raised to 70 deg.CAnd (4) reacting. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping with ethanol to obtain 13.00mg yellow solid, i.e. compound 29 (M + H) + :404)。
Example 30: synthesis of Compound 30 (5- (6-methyl-5- (1- ((5-methylpyridin-2-yl) methyl) -1H-pyrrol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 30-1
Compound 16-2 (100 mg), 2- (chloromethyl) -5-methylpyridine (98.75 mg) and Cs 2 CO 3 (228.7 mg) was mixed with DMF (5 mL) and the mixture was heated to 50 ℃ for reaction. After 3h, LCMS monitoring showed reaction complete. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography purification (DCM: meOH = 15) + :403)。
Step 2: synthesis of Compound 30
Compound 30-1 (80 mg) was mixed with 1M dilute hydrochloric acid solution (5 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. Filtering to obtain crude product, pulping with ethanol to obtain 67.23mg yellow solid, i.e. compound 30 (M + H) + :375)。
Example 31: synthesis of compound 31 (4- ((3- (3-chloro-6- (2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl) pyridazin-4-yl) -1H-pyrrol-1-yl) methyl) benzonitrile)
Step 1: synthesis of Compound 31-1
Compound M2 (10 mg), 4- (chloromethyl) benzonitrile (14.35 mg) and Cs 2 CO 3 (31.05 mg) was mixed with DMF (1 mL) and the mixture was heated to 50 ℃ and the reaction mixture was cooledShould be used. After 3h, LCMS monitoring showed reaction complete. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline solution, drying and concentrating to obtain a crude product. Column chromatography separation and purification (DCM: meOH = 40) + :418,420)。
Step 2: synthesis of Compound 31
Compound 31-1 (8 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 3h, LCMS monitoring indicated complete reaction. Direct reverse phase column preparation liquid phase freeze-drying to obtain 0.87mg white solid, namely compound 31 (M + H) + :405,407)。
Example 32: synthesis of Compound 32 (4- ((3- (6- (2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl) -3-methoxypyridazin-4-yl) -1H-pyrrol-1-yl) methyl) benzonitrile)
Step 1: synthesis of Compound 32-1
Compound 31-1 (10 mg) and sodium methoxide (12.95 mg) were mixed in methanol (2 mL), and the mixture was heated to 70 ℃ to react. After 12h, LCMS monitoring indicated complete reaction. Spin-drying methanol, dissolving the product with ethyl acetate, filtering to remove insoluble salt, and spin-drying the filtrate to obtain 6mg yellow solid, i.e. compound 32-1 (M + H) + :429)。
Step 2: synthesis of Compound 35
Compound 32-1 (6 mg) was mixed with 1M diluted hydrochloric acid solution (2 mL), and the mixture was heated to 40 ℃ to react. After 10h, LCMS monitoring indicated complete reaction. Direct reverse phase column preparation liquid phase freeze-drying to obtain 0.86mg white solid, namely compound 32 (M + H) + :401)。
Example 33: synthesis of compound 33 (5- (5- (1- (4-hydroxybenzyl) -1H-pyrrol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 33
A25 ml three-necked flask was charged with Compound 15 (25 mg) dissolved in DCM (5 ml), N 2 Protecting, cooling in ice bath, and dropwise adding BBr into the reaction solution 3 (0.1 ml), and reacted for 3 hours under ice bath. The reaction was quenched by slowly dropping saturated sodium bicarbonate solution into the reaction solution, the reaction solution was evaporated to dryness, and the product was isolated by column chromatography (DCM: meOH = 10).
LCMS：[M+H] + ＝376.13
Example 34: synthesis of Compound 34 (5- (5- (1- (3-hydroxybenzyl) -1H-pyrrol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 34
Compound 18 (30 mg) was added to a 25ml three-necked flask, dissolved in DCM (5 ml), and N 2 Protecting, cooling in ice bath, and dropwise adding BBr into the reaction solution 3 (0.15 ml), and reacted for 3 hours under ice bath. The reaction was quenched by slowly dropping saturated sodium bicarbonate solution into the reaction solution, the reaction solution was evaporated to dryness, and the product was isolated by column chromatography (DCM: meOH = 10).
LCMS：[M+H] + ＝376.13
Example 35: synthesis of Compound 35 (5- (5- (3-benzyl-1H-pyrrol-1-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 35-1
In a 100ml three-necked flask, compound M1 (200 mg) and phenyl (1H-pyridine) were addedPyrrol-3-yl) methanone (154 mg), cuI (15 mg), cs 2 CO 3 (500 mg) in DMSO (10 mL), N 2 Protection, and oil bath reaction at 70 ℃ for 4h. Cooling to room temperature, diluting the reaction solution with water, extracting with ethyl acetate, drying the organic phase with anhydrous sodium sulfate, and separating the product by column chromatography (PE: EA = 1:1) to obtain 150mg of a pale yellow solid, i.e., compound 35-1.
Step 2: synthesis of Compound 35-2
A50 mL single-necked flask was charged with Compound 35-1 (150 mg) and NaBH 4 (200 mg) was dissolved in THF (10 mL) and reacted at room temperature for 12h. The reaction solution was quenched by adding water, evaporated to dryness, and the product was isolated by column chromatography (DCM: meOH = 15.
And step 3: synthesis of Compound 35-3
A50 mL single-neck flask was charged with Compound 35-2 (100 mg), dissolved in DCM (10 mL), cooled in ice bath, and Et was added dropwise to the reaction mixture 3 SiH (0.2 ml), and finally TFA (0.5 ml) was added dropwise and reacted for 0.5h in ice bath. The reaction solution was quenched by adding saturated sodium bicarbonate solution. The reaction solution was directly evaporated to dryness and the product was isolated by column chromatography (DCM: meOH = 20).
And 4, step 4: synthesis of Compound 35
In a 25mL single-necked flask, 35-3 (50 mg) was added and dissolved in 1M hydrochloric acid (4 mL) and reacted at 70 ℃ for 3 hours. Cooling to room temperature, regulating the pH of the reaction solution to be neutral by using a saturated sodium bicarbonate solution, separating out a white solid, carrying out suction filtration, washing a filter cake with water, and drying. 15mg of a white solid, compound 35 (purity 99.16%) was obtained.
LCMS：[M+H] + ＝360.14
Example 36: synthesis of Compound 36 (5- (5- (3- (4-fluorobenzyl) -1H-pyrrol-1-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 36-1
Adding AlCl into a 100ml three-mouth bottle 3 (1.7 g), suspended in DCM (50 mL), N 2 After protection, 4-fluorobenzoyl chloride (0.7 g) was added dropwise to the reaction mixture at room temperature, and after 15 minutes of reaction, a solution of 1- (benzenesulfonyl) -1H-pyrrole in DCM was added dropwise and the reaction was carried out at room temperature for 2 hours. 50ml of ice water is added into the reaction solution, the mixture is stirred vigorously for 30 minutes, DCM is used for extraction, the organic phase is dried by anhydrous sodium sulfate, and the organic phase is evaporated to dryness to obtain 1.3g of white solid, namely the compound 36-1.
Step 2: synthesis of Compound 36-2
Compound 36-1 (1.3 g) was added to a 250mL single-necked flask and dissolved in 1,4-dioxane (40 mL) and 4M NaOH (40 mL) and reacted at room temperature for 12h. Diluting the reaction solution with water, extracting with EA for three times, drying the organic phase with anhydrous sodium sulfate, and evaporating the reaction solution to dryness to obtain 0.6g of light yellow solid, namely the compound 36-2.
And step 3: synthesis of Compound 36-3
A100 ml three-necked flask was charged with Compound M1 (200 mg), 4-fluorophenyl (1H-pyrrol-3-yl) methanone (154 mg), cuI (15 mg), cs 2 CO 3 (500 mg) in DMSO (10 mL), N 2 Protection, and oil bath reaction at 70 ℃ for 4h. Cooling to room temperature, diluting the reaction solution with water, extracting with ethyl acetate, drying the organic phase with anhydrous sodium sulfate, and separating the product by column chromatography (PE: EA = 1:1) to obtain 150mg of a pale yellow solid, i.e., compound 36-3.
And 4, step 4: synthesis of Compound 36-4
A50 mL single-necked flask was charged with Compound 36-3 (150 mg) and NaBH 4 (200 mg) was dissolved in THF (10 mL) and reacted at room temperature for 12h. The reaction solution was quenched by adding water, the reaction solution was evaporated to dryness, and the product was isolated by column chromatography (DCM: meOH = 15.
And 5: synthesis of Compound 36-5
Compound 36-4 (100 mg) was added to a 50mL single-necked flask, dissolved in DCM (10 mL), cooled in ice bath, and Et was added dropwise to the reaction mixture 3 SiH (0.2 ml), and finally TFA (0.5 ml) was added dropwise and reacted for 0.5h in ice bath. The reaction solution was quenched by adding saturated sodium bicarbonate solution. Directly evaporating to drynessThe product was isolated by column chromatography (DCM: meOH = 20) as a white solid, compound 36-5, 90 mg.
And 6: synthesis of Compound 36
In a 25mL single-necked flask, compound 36-5 (50 mg) was dissolved in 1M hydrochloric acid (4 mL) and reacted at 70 ℃ for 3 hours. Cooling to room temperature, adjusting the pH of the reaction solution to be neutral by using a saturated sodium bicarbonate solution, separating out a white solid, performing suction filtration, washing a filter cake with water, and drying. 15mg of a white solid, compound 36 (purity 99.16%) is obtained.
LCMS：[M+H] + ＝378.13
Example 37: synthesis of Compound 37 (5- (5- (3- (4-methoxybenzyl) -1H-pyrrol-1-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 37-1
Adding AlCl into a 100ml three-mouth bottle 3 (1.7 g), suspended in DCM (50 mL), N 2 After the protection, 4-methoxybenzoyl chloride (0.7 g) was added dropwise to the reaction mixture at room temperature, and after 15 minutes of reaction, a solution of 1- (benzenesulfonyl) -1H-pyrrole in DCM was added dropwise and the reaction was carried out at room temperature for 2 hours. 50ml of ice water was added to the reaction solution, stirred vigorously for 30 minutes, extracted with DCM, dried over anhydrous sodium sulfate of the organic phase and evaporated to dryness to obtain 1.3g of a white solid, compound 37-1.
Step 2: synthesis of Compound 37-2
A250 mL single-necked flask was charged with compound 37-1 (1.3 g), dissolved in 1,4-dioxane (40 mL) and 4M NaOH (40 mL), and reacted at room temperature for 12h. And (3) diluting the reaction solution by adding water, extracting by EA (ethylene-acetic acid) for three times, drying the organic phase by anhydrous sodium sulfate, and evaporating the reaction solution to dryness to obtain 0.7g of light yellow solid, namely the compound 37-2.
And step 3: synthesis of Compound 37-3
In a 100ml three-necked flask, compound M1 (200 mg), 4-methoxyphenyl (1H-pyrrol-3-yl) methanone (154 mg), cuI (15 mg), cs 2 CO 3 (500 mg) in DMSO (10 mL), N 2 Protection, and oil bath reaction at 70 ℃ for 4h. Cooling to room temperature, diluting the reaction solution with water, extracting with ethyl acetate, drying the organic phase with anhydrous sodium sulfate, and separating the product by column chromatography (PE: EA = 1:1) to obtain 150mg of a pale yellow solid, i.e., compound 37-3.
And 4, step 4: synthesis of Compound 37-4
A50 mL single-necked flask was charged with Compound 37-3 (150 mg) and NaBH 4 (200 mg) was dissolved in THF (10 mL) and reacted at room temperature for 12h. The reaction solution was quenched by adding water, evaporated to dryness, and the product was isolated by column chromatography (DCM: meOH = 15.
And 5: synthesis of Compound 37-5
A50 mL single vial was charged with compound 37-4 (100 mg), dissolved in DCM (10 mL), cooled in ice bath, and Et was added dropwise to the reaction mixture 3 SiH (0.2 ml), and finally TFA (0.5 ml) was added dropwise and reacted for 0.5h in ice bath. The reaction was quenched by adding saturated sodium bicarbonate solution to the reaction solution. The reaction was directly evaporated to dryness and the product was isolated by column chromatography (DCM: meOH = 20).
Step 6: synthesis of Compound 37
A25 mL single vial was charged with 37-5 (90 mg) of compound, dissolved in 1M hydrochloric acid (4 mL) and reacted at 70 ℃ for 3h. Cooling to room temperature, regulating the pH of the reaction solution to be neutral by using a saturated sodium bicarbonate solution, separating out a white solid, carrying out suction filtration, washing a filter cake with water, and drying. 55mg of a white solid, compound 37 (purity 99.16%) was obtained.
LCMS：[M+H] + ＝390.15
Example 38: synthesis of Compound 38 (5- (5- (3- (4-hydroxybenzyl) -1H-pyrrol-1-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 38
25ml of threeCompound 37 (25 mg) was added to the vial, dissolved in DCM (5 ml), N 2 Protecting, cooling in ice bath, and dropwise adding BBr into the reaction solution 3 (0.1 ml), and reacted for 3 hours in an ice bath. The reaction was quenched by slowly dropping saturated sodium bicarbonate solution into the reaction solution, the reaction solution was evaporated to dryness, and the product was isolated by column chromatography (DCM: meOH = 10).
LCMS：[M+H] + ＝376.13
Example 39: synthesis of Compound 39 (4- ((1- (6- (2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl) -3-methylpyridazin-4-yl) -1H-pyrrol-3-yl) methyl) benzonitrile)
Step 1: synthesis of Compound 39-1
Adding AlCl into a 100ml three-mouth bottle 3 (1.7 g), suspended in DCM (50 mL), N 2 After the protection, 4-cyanobenzoyl chloride (0.7 g) was added dropwise to the reaction mixture at room temperature, and the reaction was carried out for 15 minutes, then a solution of 1- (benzenesulfonyl) -1H-pyrrole in DCM was added dropwise thereto, and the reaction was carried out for 2 hours at room temperature. 50ml of ice water was added to the reaction solution, stirred vigorously for 30 minutes, extracted with DCM, dried over anhydrous sodium sulfate of the organic phase and evaporated to dryness to obtain 1.3g of a white solid, compound 39-1.
Step 2: synthesis of Compound 39-2
A250 mL single-necked flask was charged with compound 39-1 (1.3 g), dissolved in 1,4-dioxane (40 mL) and 4M NaOH (40 mL), and reacted at room temperature for 12h. Diluting the reaction solution with water, extracting with EA for three times, drying the organic phase with anhydrous sodium sulfate, and evaporating the reaction solution to dryness to obtain 0.7g of light yellow solid, namely the compound 39-2.
And step 3: synthesis of Compound 39-3
In a 100ml three-necked flask, compound M1 (200 mg), 4-cyanophenyl (1H-pyrrol-3-yl) methanone (154 mg), cuI (15 mg), cs 2 CO 3 (500 mg) in DMSO (10 mL), N 2 Protection, and oil bath reaction at 70 ℃ for 4h.Cooling to room temperature, diluting the reaction solution with water, extracting with ethyl acetate, drying the organic phase with anhydrous sodium sulfate, and separating the product by column chromatography (PE: EA = 1:1) to obtain 150mg of a pale yellow solid, i.e., compound 39-3.
And 4, step 4: synthesis of Compound 39-4
A50 mL single-necked flask was charged with Compound 7-3 (150 mg) and NaBH 4 (200 mg) was dissolved in THF (10 mL) and reacted at room temperature for 12h. The reaction solution was quenched by adding water, the reaction solution was evaporated to dryness, and the product was isolated by column chromatography (DCM: meOH = 15.
And 5: synthesis of Compound 39-5
A50 mL single vial was charged with 39-4 (100 mg) dissolved in DCM (10 mL), cooled in ice bath, and Et was added dropwise to the reaction mixture 3 SiH (0.2 ml), and finally TFA (0.5 ml) was added dropwise and reacted for 0.5h in ice bath. The reaction was quenched by adding saturated sodium bicarbonate solution to the reaction solution. The reaction was directly evaporated to dryness and the product was isolated by column chromatography (DCM: meOH = 20).
And 7: synthesis of Compound 39
A25 mL single vial was charged with 39-5 (50 mg) dissolved in 1M hydrochloric acid (4 mL) and reacted at 70 ℃ for 3h. Cooling to room temperature, adjusting the pH of the reaction solution to be neutral by using a saturated sodium bicarbonate solution, separating out a white solid, performing suction filtration, washing a filter cake with water, and drying. 15mg of a white solid, compound 39 (purity 99.16%) was obtained.
LCMS：[M+H] + ＝385.13
Example 40: synthesis of Compound 40 (5- (5- (1- (4-methoxybenzyl) -1H-pyrazol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 40-1
A50 ml three-necked flask was charged with Compound M1 (100 mg), 3- (4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl) -1H-pyrazole (110 mg), pd(dppf)Cl 2 (30mg)、K 2 CO 3 (100 mg) in 1,4-dioxane (10 mL), water (2 mL), N 2 Protection, and oil bath reaction at 70 ℃ for 4h. Cooling to room temperature, diluting the reaction solution with water, extracting with ethyl acetate, drying the organic phase with anhydrous sodium sulfate, and separating the product by column chromatography (PE: EA = 1:2) to obtain 100mg of a yellow solid, i.e., compound 40-1.
Step 2: synthesis of Compound 40-2
A50 ml single-necked flask was charged with compound 40-2 (100 mg), p-methoxybenzyl chloride (110 mg), and K 2 CO 3 (100 mg) in DMF (10 ml) and reacted in an oil bath at 60 ℃ for 2h. Cooling to room temperature, diluting the reaction solution with water, extracting with ethyl acetate, drying the organic phase with anhydrous sodium sulfate, and separating the product by column chromatography (PE: EA = 1:1) to obtain 70mg of yellow solid, i.e., compound 40-2.
And step 3: synthesis of Compound 40
A25 mL single vial was charged with Compound 40-2 (70 mg) dissolved in 1M hydrochloric acid (4 mL) and reacted at 70 ℃ for 3h. Cooling to room temperature, regulating the pH of the reaction solution to be neutral by using a saturated sodium bicarbonate solution, separating out a white solid, carrying out suction filtration, washing a filter cake with water, and drying. 45mg of a white solid, compound 40 (purity 99.16%) was obtained.
LCMS：[M+H] + ＝391.14
Example 41: synthesis of Compound 41 (5- (6-methyl-5- (1- (2- (trifluoromethoxy) benzyl) -1H-pyrrol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 41-1
A50 ml single-necked flask was charged with intermediate M2 (50 mg), 1- (bromomethyl) -2- (trifluoromethoxy) benzene (74 mg), and K 2 CO 3 (100 mg) in DMF (5 ml) and reacted in an oil bath at 50 ℃ for 2h. Cooling to room temperature, diluting the reaction solution with water, extracting with ethyl acetate, and drying the organic phase with anhydrous sodium sulfateThe product was dried and isolated by column chromatography (PE: EA = 1:1) to yield 30mg of a yellow solid, compound 41-1.
Step 2: synthesis of Compound 41
A25 mL single vial was charged with Compound 41-1 (30 mg) dissolved in 1M hydrochloric acid (3 mL) and reacted at 70 ℃ for 3h. Cooling to room temperature, adjusting the pH of the reaction solution to be neutral by using a saturated sodium bicarbonate solution, separating out a white solid, performing suction filtration, washing a filter cake with water, and drying. 15mg of a white solid, compound 41 (purity 99.16%) was obtained.
LCMS：[M+H] + ＝444.12
Example 42: synthesis of Compound 42 (5- (6-methyl-5- (1- (3- (trifluoromethoxy) benzyl) -1H-pyrrol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 42-1
A50 ml single-necked flask was charged with intermediate M2 (50 mg), 1- (bromomethyl) -3- (trifluoromethoxy) benzene (74 mg), and K 2 CO 3 (100 mg) in DMF (5 ml) and reacted in an oil bath at 50 ℃ for 2h. Cooling to room temperature, diluting the reaction solution with water, extracting with ethyl acetate, drying the organic phase with anhydrous sodium sulfate, and separating the product by column chromatography (PE: EA = 1:1) to obtain 30mg of a yellow solid, i.e., compound 42-1.
Step 2: synthesis of Compound 42
A25 mL single vial was charged with compound 42-1 (30 mg) dissolved in 1M hydrochloric acid (3 mL) and reacted at 70 ℃ for 3h. Cooling to room temperature, regulating the pH of the reaction solution to be neutral by using a saturated sodium bicarbonate solution, separating out a white solid, carrying out suction filtration, washing a filter cake with water, and drying. 15mg of a white solid, compound 42 (purity 99.16%) was obtained.
LCMS：[M+H] + ＝444.12
Example 43: synthesis of Compound 43 (methyl 4- ((3- (6- (2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl) -3-methylpyridazin-4-yl) -1H-pyrrol-1-yl) methyl) benzoate)
Step 1: synthesis of Compound 43-1
A50 ml single-necked flask was charged with intermediate M2 (50 mg), methyl 4- (bromomethyl) benzoate (57 mg), and Cs 2 CO 3 (120 mg) in DMF (5 ml) and reacted in an oil bath at 50 ℃ for 2h. Cooling to room temperature, diluting the reaction solution with water, extracting with ethyl acetate, drying the organic phase with anhydrous sodium sulfate, and separating the product by column chromatography (PE: EA = 1:1) to obtain 35mg of a yellow solid, i.e., compound 43-1.
Step 2: synthesis of Compound 43
A25 mL single vial was charged with Compound 43-1 (35 mg) dissolved in 1M hydrochloric acid (3 mL) and reacted at 70 ℃ for 3h. Cooling to room temperature, regulating the pH of the reaction solution to be neutral by using a saturated sodium bicarbonate solution, separating out a white solid, carrying out suction filtration, washing a filter cake with water, and drying. 20mg of a white solid, compound 43 (purity 99.16%) was obtained.
LCMS：[M+H] + ＝418.14
Example 44: synthesis of Compound 44 (methyl 3- ((3- (6- (2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl) -3-methylpyridazin-4-yl) -1H-pyrrol-1-yl) methyl) benzoate)
Step 1: synthesis of Compound 44-1
A50 ml single-necked flask was charged with intermediate M2 (50 mg), methyl 3- (bromomethyl) benzoate (57 mg), and Cs 2 CO 3 (120 mg) in DMF (5 ml) and reacted in an oil bath at 50 ℃ for 2h. Cooling to room temperature, diluting the reaction solution with water, extracting with ethyl acetate, drying the organic phase with anhydrous sodium sulfate, and separating the product by column chromatography (PE: EA = 1:1) to obtain 35mg of a yellow solid, i.e., compound 44-1.
Step 2: synthesis of Compound 44
A25 mL single vial was charged with compound 44-1 (35 mg) dissolved in 1M hydrochloric acid (3 mL) and reacted at 70 ℃ for 3h. Cooling to room temperature, adjusting the pH of the reaction solution to be neutral by using a saturated sodium bicarbonate solution, separating out a white solid, performing suction filtration, washing a filter cake with water, and drying. 20mg of white solid, compound 44 (purity 99.16%) was obtained.
LCMS：[M+H] + ＝418.14
Example 45: synthesis of Compound 45 (5- (5- (1- (3- (hydroxymethyl) benzyl) -1H-pyrrol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 45
A25 mL three-necked flask was charged with Compound 44 (20 mg), naBH 4 (10 mg) in THF (3 mL), N 2 To the reaction solution, meOH (0.3 ml) was added dropwise under protection and oil bath at 50 ℃. The reaction was carried out at 50 ℃ for 3h. Cooling to room temperature, and dropwise adding water into the reaction liquid to quench the reaction. The reaction was evaporated to dryness directly and the product isolated by column chromatography (DCM: meOH = 10.
LCMS：[M+H] + ＝390.15
Example 46: synthesis of Compound 46 (5- (5- (1- (4- (difluoromethyl) benzyl) -1H-pyrrol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
A50 ml single-necked flask was charged with intermediate M2 (100 mg), methyl 4- (bromomethyl) benzoate (120 mg), and Cs 2 CO 3 (300 mg), dissolved in DMF (10 ml) and reacted in an oil bath at 50 ℃ for 2h. Cooling to room temperature, diluting the reaction mixture with water, extracting with ethyl acetate, andthe organic phase was dried over anhydrous sodium sulfate and the product was isolated by column chromatography (PE: EA = 1:1) to yield 80mg of a yellow solid, compound 46-1.
Step 2: synthesis of Compound 46-2
A50 mL three-necked flask was charged with 46-1 (80 mg) of Compound and NaBH 4 (50 mg) in THF (10 mL), N 2 To the reaction mixture MeOH (1 ml) was added dropwise under oil bath at 50 ℃. The reaction was carried out at 50 ℃ for 3h. Cooling to room temperature, and dropwise adding water into the reaction solution to quench the reaction. The reaction solution was directly evaporated to dryness, and the product was isolated by column chromatography (DCM: meOH = 10.
And step 3: synthesis of Compound 46-3
Compound 46-2 (45 mg) and PCC (50 mg) were added to a 50mL one-neck flask, dissolved in DCM (10 mL) and reacted at room temperature for 3h. The reaction was evaporated to dryness directly and the product was isolated by column chromatography (DCM: meOH = 15.
And 4, step 4: synthesis of Compound 46-4
A25 mL single-neck flask was charged with 46-3 (30 mg) dissolved in DCM (5 mL), cooled in ice bath, and DSAT (0.5 mL) was added dropwise to the reaction mixture, after the addition, the reaction mixture was slowly warmed to room temperature and reacted for 3h. The reaction solution was quenched by dropwise addition of saturated sodium bicarbonate solution, the reaction solution was directly evaporated to dryness, and the product was isolated by column chromatography (DCM: meOH = 15).
And 5: synthesis of Compound 46
In a 25mL single-necked flask, compound 46-4 (20 mg) was added, dissolved in MeOH (2 mL) and 1M hydrochloric acid (2 mL), and reacted at 40 ℃ for 5h. After cooling to room temperature, the reaction solution was adjusted to neutral pH with sodium bicarbonate, evaporated to dryness, and the product was isolated by column chromatography (DCM: meOH =10 1) to give 10mg of a white solid, compound 46 (purity 99.16%).
LCMS：[M+H] + ＝410.14
Example 47: synthesis of Compound 47 (5- (5- (1- (3- (difluoromethyl) benzyl) -1H-pyrrol-3-yl) -6-methylpyridin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 47-1
A50 ml single-necked flask was charged with intermediate M2 (100 mg), methyl 3- (bromomethyl) benzoate (120 mg), and Cs 2 CO 3 (300 mg) in DMF (10 ml) and reacted in an oil bath at 50 ℃ for 2h. Cooling to room temperature, diluting the reaction solution with water, extracting with ethyl acetate, drying the organic phase with anhydrous sodium sulfate, and separating the product by column chromatography (PE: EA = 1:1) to obtain 80mg of a yellow solid, i.e., compound 47-1.
And 2, step: synthesis of Compound 47-2
A50 mL three-necked flask was charged with 47-1 (80 mg) of NaBH 4 (50 mg) in THF (10 mL), N 2 To the reaction solution, meOH (1 ml) was added dropwise under protection and oil bath at 50 ℃. The reaction was carried out at 50 ℃ for 3h. Cooling to room temperature, and dropwise adding water into the reaction liquid to quench the reaction. The reaction solution was directly evaporated to dryness, and the product was isolated by column chromatography (DCM: meOH = 10.
And step 3: synthesis of Compound 47-3
Compound 47-2 (45 mg) and PCC (50 mg) were added to a 50mL single-necked flask, dissolved in DCM (10 mL) and reacted at room temperature for 3h. The reaction was evaporated to dryness directly and the product was isolated by column chromatography (DCM: meOH = 15.
And 4, step 4: synthesis of Compound 47-4
A25 mL single-neck flask was charged with 47-3 (30 mg) dissolved in DCM (5 mL), cooled in ice bath, and DSAT (0.5 mL) was added dropwise to the reaction mixture, after the addition, the reaction mixture was slowly warmed to room temperature and reacted for 3h. The reaction solution was quenched by dropwise addition of saturated sodium bicarbonate solution, the reaction solution was directly evaporated to dryness, and the product was isolated by column chromatography (DCM: meOH = 15).
And 5: synthesis of Compound 47
In a 25mL single-necked flask, compound 47-4 (20 mg) was added, dissolved in MeOH (2 mL) and 1M hydrochloric acid (2 mL), and reacted at 40 ℃ for 5h. After cooling to room temperature, the reaction solution was adjusted to neutral pH with sodium bicarbonate, evaporated to dryness, and the product was isolated by column chromatography (DCM: meOH =10 1) to give 10mg of a white solid, compound 47 (purity 99.16%).
LCMS：[M+H] + ＝410.14
Example 48: synthesis of Compound 48 (5- (6-methyl-5- (1- (pyridin-4-ylmethyl) -1H-pyrrol-3-yl) pyridin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 48-1
Compound 16-2 (59 mg), 4- (bromomethyl) pyridine (40.96 mg), cs 2 CO 3 (129.31 mg) was mixed in DMF (6 mL) and reacted at room temperature. After 2h, TLC monitoring indicated complete reaction. The reaction solution was poured into appropriate amount of water and mixed well, extracted three times with ethyl acetate, washed with saturated brine, dried, concentrated, and purified by preparative TLC (DCM/MeOH = 20/1) to give 30mg of yellow solid, i.e. compound 48-1 (M + H) + :389)。
Step 2: synthesis of Compound 48
Compound 48-1 (30 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. The reaction solution was spun dry and slurried with dichloromethane to give 4.4mg of a yellow solid, compound 48 (M + H) + :361)。
1 H NMR(600MHz,DMSO-d6)δ11.89(s,1H),11.72(s,1H),8.77(d,J＝5.7Hz,2H),8.55(s,1H),8.44(d,J＝5.8Hz,1H),7.82(s,1H),7.55(d,J＝5.6Hz,2H),7.19(t,J＝2.5Hz,1H),6.83(s,1H),5.53(s,2H),2.84(s,3H).
Example 49: synthesis of Compound 49 (5- (6-methyl-5- (1- (4-methylbenzyl) -1H-pyrrol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 49-1
Mixing compound 16-2 (59 mg), 4-methyl benzyl chloride (41.85 mg), and Cs 2 CO 3 (129.31 mg) was mixed with DMF (6 mL) and the mixture was heated to 50 ℃ for reaction. After 2h, TLC monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline, drying, concentrating, and purifying by preparative TLC (PE/EA = 1/1) to obtain 70mg of yellow solid, namely the compound 49-1 (M + H) + :402)。
Step 2: synthesis of Compound 49
Compound 49-1 (70 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. The reaction solution was spun dry and slurried with dichloromethane to give 15.2mg of a white solid, compound 49 (M + H) + :374)。
1 H NMR(600MHz,Methanol-d4)δ8.73(s,1H),8.66(s,1H),7.76(d,J＝2.1Hz,1H),7.18(s,4H),7.02(t,J＝2.6Hz,1H),6.87(t,J＝2.5Hz,1H),5.20(s,2H),2.90(s,3H),2.32(s,3H).
Example 50: synthesis of Compound 50 (6- ((3- (6- (2,4-dioxy-1,2,3,4-tetrahydropyrimidin-5-yl) -3-methylpyridazin-4-yl) -1H-pyrrol-1-yl) methyl) nicotinonitrile)
Step 1: synthesis of Compound 50-1
Compound 16-2 (59 mg), 6- (bromomethyl) nicotinonitrile (58.64 mg), cs 2 CO 3 (129.31 mg) was mixed in DMF (6 mL) and reacted at room temperature. After 2h, TLC monitoring showed the reaction was complete. The reaction solution was poured into appropriate amount of water and mixed well, extracted three times with ethyl acetate, washed with saturated brine, dried, concentrated, and purified by preparative TLC (DCM/MeOH = 20/1) to give 75mg of yellow solid, i.e. compound 50-1 (M + H) + :414)。
Step 2: synthesis of Compound 50
Compound 50-1 (75 mg)) Mixed with 1M diluted hydrochloric acid solution (2 mL), and heated to 70 ℃ for reaction. After 5h, LCMS monitoring indicated complete reaction. The reaction solution was spun dry and slurried with dichloromethane to give 62.6mg of a yellow solid, compound 50 (M + H) + :386)。
1 H NMR(600MHz,DMSO-d6)δ11.46(s,1H),11.43(s,1H),9.02(d,J＝2.1Hz,1H),8.31(dd,J＝8.2,2.2Hz,1H),8.28(d,J＝3.6Hz,1H),8.24(s,1H),7.52(d,J＝2.1Hz,1H),7.23(d,J＝8.2Hz,1H),7.07(t,J＝2.5Hz,1H),6.58(dd,J＝2.9,1.9Hz,1H),5.44(s,2H),2.76(s,3H).
Example 51: synthesis of Compound 51 (5- (6-methyl-5- (1- (3-methylbenzyl) -1H-pyrrol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 51-1
Mixing the compound 16-2 (59 mg), 3-methylbenzyl chloride (41.67 mg) and Cs 2 CO 3 (129.31 mg) was mixed with DMF (6 mL) and the mixture was heated to 50 ℃ for reaction. After 2h, TLC monitoring showed the reaction was complete. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline, drying, concentrating, and purifying by preparative TLC (PE/EA = 1/1) to obtain 72mg of yellow solid, namely the compound 51-1 (M + H) + :402)。
Step 2: synthesis of Compound 51
Compound 51-1 (72 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. The reaction solution was spun dry and slurried with dichloromethane to give 58.3mg of a white solid, compound 51 (M + H) + :374)。
1 H NMR(600MHz,DMSO-d6)δ12.04(s,1H),11.80(s,1H),8.61(s,1H),8.48(d,J＝5.6Hz,1H),7.87(d,J＝2.1Hz,1H),7.25(t,J＝7.5Hz,1H),7.17–7.08(m,4H),6.80(t,J＝2.4Hz,1H),5.21(s,2H),2.86(s,3H),2.29(s,3H).
Example 52: synthesis of Compound 52 (5- (6-methyl-5- (1- (2-methylbenzyl) -1H-pyrrol-3-yl) pyridin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 52-1
Compound 16-2 (59 mg), 2-methylbenzyl chloride (41.67 mg), cs 2 CO 3 (129.31 mg) was mixed with DMF (6 mL) and the mixture was heated to 50 ℃ for reaction. After 2h, TLC monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline, drying, concentrating, and purifying by preparative TLC (PE/EA = 1/1) to obtain 68mg of yellow solid, namely the compound 52-1 (M + H) + :402)。
And 2, step: synthesis of Compound 52
Compound 52-1 (72 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. The reaction solution was spun dry and slurried with dichloromethane to give 63.1mg of a white solid, compound 52 (M + H) + :374)。
1 H NMR(600MHz,DMSO-d6)δ11.99(s,1H),11.78(s,1H),8.59(s,1H),8.47(d,J＝5.9Hz,1H),7.76(s,1H),7.25–7.21(m,2H),7.18(dq,J＝8.7,3.9Hz,1H),7.05(t,J＝2.5Hz,1H),6.93(d,J＝7.4Hz,1H),6.81(t,J＝2.4Hz,1H),5.29(s,2H),2.84(s,3H),2.31(s,3H).
Example 53: synthesis of Compound 53 (5- (5- (1- (4-aminobenzyl) -1H-pyrrol-3-yl) -6-methylpyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 53-1
Mixing compound 16-2 (59 mg), 4-nitrobenzyl chloride (50.90 mg), cs 2 CO 3 (129.31 mg) was mixed in DMF (6 mL) and reacted at room temperature. After the reaction time of 2 hours, the reaction solution is stirred,TLC monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline, drying, concentrating, and performing TLC purification (PE/EA = 1/1) to obtain 77mg of yellow solid, namely a compound 53-1 (M + H) + :433)。
Step 2: synthesis of Compound 53-2
Compound 53-1 (72 mg) and palladium on carbon (10 mg) were mixed with absolute ethanol (5 mL), and the mixture was heated to 80 ℃ to react. After 2h, LCMS monitoring showed reaction complete. The reaction mixture was spin-dried, filtered to remove palladium on carbon, and spin-dried to give 63.5mg of a white solid, i.e., compound 53-2 (M + H) + :403)。
And step 3: synthesis of Compound 53
Compound 53-2 (63.5 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. The reaction solution was spun dry and slurried with dichloromethane to give 6.9mg of a white solid, compound 53 (M + H) + :375)。
1 H NMR(600MHz,DMSO-d6)δ11.77(s,1H),11.66(s,1H),8.41(d,J＝16.2Hz,2H),7.68(s,1H),7.27–7.20(m,2H),7.06(t,J＝2.5Hz,1H),6.95(s,2H),6.68(s,1H),5.14(s,2H),2.80(s,2H),1.24(s,3H).
Example 54: synthesis of Compound 54 (5- (6-methyl-5- (1- (4- (methylsulfonyl) benzyl) -1H-pyrrol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 54-1
Mixing compound 16-2 (59 mg), 4-methanesulfonyl chlorobenzyl (60.58 mg), cs 2 CO 3 (129.31 mg) was mixed in DMF (6 mL) and reacted at room temperature. After 2h, TLC monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline, drying, concentrating, and performing preparative TLC purification (PE/EA = 1/1) to obtain 62mg of white solid, namely the compound 54-1 (M + H) + :466)。
Step 2: synthesis of Compound 54
Compound 54-1 (62 mg) was mixed with 1M dilute hydrochloric acid solution (2 mL), and the mixture was heated to 70 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. The reaction solution was spun dry and slurried with dichloromethane to give 21.8mg of a white solid, compound 54 (M + H) + :438)。
1 H NMR(600MHz,DMSO-d6)δ11.95(s,1H),11.76(s,1H),8.57(s,1H),8.46(d,J＝6.0Hz,1H),7.96–7.91(m,2H),7.87(s,1H),7.56–7.52(m,2H),7.18(dd,J＝3.0,2.0Hz,1H),6.81(t,J＝2.4Hz,1H),5.40(s,2H),3.20(s,3H),2.85(s,3H).
Example 55: synthesis of Compound 55 (5- (6-methoxy-5- (1- (4-methoxybenzyl) -1H-pyrrol-3-yl) pyridazin-3-yl) pyrimidine-2,4 (1H, 3H) -dione)
Step 1: synthesis of Compound 55-1
4-bromo-1,2-dihydropyridazine-3,6-dione (2.00 g), 3- (4,4,5,5-tetramethyl-1,3,2-dioxaboron-2-yl) -1- (triisopropylsilyl) -1H-pyrrole (7.30 g), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride dichloromethane complex (0.42 g), cs 2 CO 3 (17.06 g) was mixed with dioxane (100 mL) and water (30 mL) and heated to 70 ℃ under nitrogen atmosphere. After 3h, LCMS monitoring indicated complete reaction. Pouring the reaction solution into a proper amount of water, mixing uniformly, extracting with ethyl acetate for three times, washing with saturated saline, drying, concentrating, and purifying by column chromatography (DCM/MeOH = 20/1) to obtain 0.83g of yellow liquid, namely a compound 55-1 (M + H) + :334)。
Step 2: synthesis of Compound 55-2
Compound 55-1 (0.83 g) was dissolved in phosphorus oxychloride (10 mL) and reacted by warming to 100 ℃. After 1h, LCMS monitoring indicated complete reaction. Slowly adding the reaction solution into water, quenching phosphorus oxychloride, extracting with ethyl acetate for three times, washing with saturated saline solution, drying, concentrating, and purifying with columnChromatographic purification (PE/EA = 1/1) gave 0.23g of a white solid, i.e. compound 55-2 (M + H) + :215)。
And step 3: synthesis of Compound 55-3
Compounds 55-2 (0.25 g), (2,4-dimethoxypyrimidin-5-yl) boronic acid (0.25 g), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride dichloromethane complex (0.05 g), K 2 CO 3 (0.32 g) was mixed with a mixed solvent of dioxane (10 mL) and water (2 mL), and the mixture was heated to 60 ℃ under nitrogen atmosphere to react. After 1h, LCMS monitoring indicated complete reaction. The reaction solution was poured into appropriate amount of water and mixed well, extracted three times with ethyl acetate, washed with saturated brine, dried, concentrated, and purified by preparative TLC (DCM/MeOH = 20/1) to obtain 0.14g of white solid, i.e. compound 55-3 (M + H) + :319)。
And 4, step 4: synthesis of Compound 55-4
Mixing compound 55-3 (0.14 g), 4-methoxy benzyl chloride (0.13 g), cs 2 CO 3 (0.27 g) was mixed with DMF (10 mL), and the mixture was heated to 50 ℃ for reaction. After 2h, TLC monitoring indicated complete reaction. The reaction solution was poured into appropriate amount of water and mixed well, extracted three times with ethyl acetate, washed with saturated brine, dried, concentrated, and purified by preparative TLC (DCM/MeOH = 20/1) to give 143mg of white solid, i.e. compound 55-4 (M + H) + :439)。
And 5: synthesis of Compound 55-5
Compound 55-4 (0.14 g) and sodium methoxide (0.18 g) were mixed in methanol (20 mL), and the mixture was heated to 60 ℃ to carry out a tube-sealing reaction. After 12h, LCMS monitoring indicated complete reaction. The reaction solution was poured into appropriate amount of water and mixed well, extracted three times with dichloromethane, washed with saturated brine, dried, concentrated, and purified by preparative TLC (DCM/MeOH = 20/1) to give 48mg of white solid, i.e. compound 55-5 (M + H) + :434)。
Step 6: synthesis of Compound 55
Compound 55-5 (48 mg) was mixed with 1M diluted hydrochloric acid solution (2 mL), and the mixture was heated to 50 ℃ to react. After 5h, LCMS monitoring indicated complete reaction. The reaction solution was spun dry and the preparative liquid phase was purified to give 30mg of a gray solid, compound 55 (M + H) + :406)。
1 H NMR(600MHz,DMSO-d6)δ11.43(s,1H),8.24(s,1H),8.12(s,1H),7.66(s,1H),7.23(d,J＝8.2Hz,2H),6.97(s,1H),6.92(d,J＝8.2Hz,2H),6.63(s,1H),5.11(s,2H),4.13(s,3H),3.73(s,3H).
The following examples were synthesized using the methods described above, or analogous methods using the corresponding intermediates.
Comparative example 1
Comparative compound 1 was synthesized according to the procedure of WO2019168744A1 example 2,
pharmacological experiments
Example 1: detection of enzymatic Activity at cellular level
Calu-6 cells were digested using TM buffer (25mM Tris,5mM MgCl) 2 pH 7.5) and plated at 25000 cells in 96-well plates at 100. Mu.L/well. TM buffer was used to prepare gradient concentration compound solutions, and 50. Mu.L of DMSO solutions of test compounds were added to each well at respective concentrations of 20000, 6666.7, 2222.2, 740.7, 246.9, 82.3, 27.4, 9.1, 3.0, 1.0, 0.3, 0nM (final DMSO concentration was 0.625%). Pre-incubating for 30min at 37 ℃ by using a constant-temperature horizontal shaking table, adding 50 mu L of 800 mu M AMP solution into each hole, continuing incubating for 120min by using a constant-temperature horizontal shaking table at 37 ℃, centrifuging a 96-well plate, transferring 50 mu L of supernate into a new 96-well plate for each hole, adding 50 mu L of 130 mu M ATP solution and 100 mu L of Cell-tilt Glo working solution into each hole, oscillating, uniformly mixing, incubating for 10min at room temperature, and labeling with multifunctional enzymeLuminescence values were read by the luminometer and Luminescence readings were converted to percent inhibition:
percent inhibition = (1-reading/max) × 100.
"maximum" is DMSO control.
Curve fitting was performed using GraphPad Prism software and IC50 values were obtained.
The enzymatic IC50 data of the compounds of the examples at the cellular level of Calu-6 are shown in Table 1.
TABLE 1
| Name of Compound | IC50(nM) | Name of Compound | IC50(nM) |
| 1 | 2084 | 29 | 114 |
| 2 | 54.4 | 30 | 12.4 |
| 3 | 49 | 31 | 4.8 |
| 4 | 37.4 | 32 | 4.6 |
| 5 | 25.1 | 33 | 5.7 |
| 6 | 455 | 34 | 8.2 |
| 7 | 462 | 35 | 95 |
| 8 | 617 | 36 | 73 |
| 9 | 28 | 37 | 96 |
| 10 | 9.4 | 38 | 71 |
| 11 | 173 | 39 | 79 |
| 12 | 308 | 40 | 50 |
| 13 | 239 | 41 | 63 |
| 14 | 3.1 | 42 | 30 |
| 15 | 2.1 | 43 | 10.3 |
| 16 | 9.5 | 44 | 7.3 |
| 17 | 22.2 | 45 | 31.6 |
| 18 | 10.2 | 46 | 24.2 |
| 19 | 59 | 47 | 34.7 |
| 20 | 83 | 48 | 39.8 |
| 21 | 23 | 49 | 14 |
| 22 | 49 | 50 | 21.8 |
| 23 | 376 | 51 | 16 |
| 24 | 121 | 52 | 19.5 |
| 25 | 26.6 | 53 | 18 |
| 26 | 14.7 | 54 | 21.4 |
| 27 | 13.5 | 55 | 96.3 |
| 28 | 32.6 | D1 | 49.1 |
The compounds of the present invention have good activity and unexpectedly, the present invention R 3 The substituent meta-substituted compound has significantly enhanced activity compared to ortho-substituted compound (table 2).
TABLE 2
While the present invention has been fully described by way of embodiments thereof, it is to be noted that various changes and modifications will be apparent to those skilled in the art. Such changes and modifications are intended to be included within the scope of the appended claims.
Claims (11)
- A compound of formula (I), a tautomer, a deuteron, or a pharmaceutically acceptable salt thereof:
wherein,R 1 selected from phenyl or 5-6 membered heteroaryl, said phenyl or 5-6 membered heteroaryl being unsubstituted or substituted by 1,2 or 3 substituents R 3 The substitution is carried out on the raw materials,R 3 is selected from C 1-6 Alkyl, - (C) 1-4 Alkylene radical) 0-1 -Cyc、-O-(C 1-4 Alkylene radical) 0-1 -Cyc、-S-(C 1-4 Alkylene radical) 0-1 -Cyc、-NH-(C 1-4 Alkylene radical) 0-1 -Cyc、-NH-C 1-6 Alkyl, -N (C) 1-6 Alkyl radical) 2 、-O-C 1-6 Alkyl or-S-C 1-6 Alkyl radical, R 3 Optionally unsubstituted or further substituted by one or more R 4 Substituted by a substituent;cyc is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl or 5-to 10-membered heteroaryl, said C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl or 5-to 10-membered heteroaryl unsubstituted or substituted by 1,2 or 3 substituents R 5 Substituted;R 4 or R 5 Each independently selected from H, hydroxy, amino, halogen, cyano, nitro, -OR a 、-SR a 、＝O、＝S、-C(O)R a 、-C(S)R a 、-C(O)OR a 、-C(S)OR a 、-C(O)N(R a ) 2 、-N(R a ) 2 、-S(O) 2 R a 、-O-S(O 2 )OR a 、-O-S(O) 2 R a Or R a Said R is a Each independently selected from H, C 1-6 Alkyl or C 3-6 Cycloalkyl radical, R a Unsubstituted or further substituted by one or more groups selected from halogen, hydroxy, C 1-3 Alkyl or cyano;R 2 selected from hydrogen, halogen, cyano, C 1-3 Alkyl radical, C 1-3 Alkoxy radical, C 2-4 Alkenyl, halo C 2-4 Alkenyl or C 2-4 Alkynyl. - The compound, tautomer, deuteron, or pharmaceutically acceptable salt thereof according to claim 1, wherein R is 1 Selected from phenyl or 5-6 membered heteroaryl, optionally containing 1 or 2 heteroatoms each independently selected from N, O or S, and said heteroaryl ring group being unsubstituted or substituted with 1,2 or 3 substituents R 3 Substituted; preferably R 1 Is selected from
The R is 1 Unsubstituted or substituted by 1,2 or 3 substituents R 3 And (4) substituting.
- The compound, tautomer, deuteron or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R is 3 Is substituted in meta position.
- The compound, tautomer, deuteron or pharmaceutically acceptable salt thereof according to any one of claims 1-3, wherein R is 3 Is selected from C 1-6 Alkyl, -C 1-3 Alkylene-phenyl, -C 1-3 alkylene-C 3-6 Cycloalkyl or-C 1-3 Alkylene- (5-to 10-membered heteroaryl), said R 3 Optionally selected from H, cyano, halogen, hydroxy, amino, C 1-3 Alkyl radical, C 1-3 Hydroxyalkyl radical, C 1-3 Haloalkyl, C 1-3 Alkoxy radical, C 1-3 Haloalkoxy, -C (= O) O-C 1-3 Alkyl or-S (= O) 2 -C 1-3 Alkyl substituent substitution; preferably R 3 Is selected from C 1-6 Alkyl, aryl, heteroaryl, and heteroaryl,
The R is 3 Optionally selected from H, cyano, halogen, hydroxy, amino, C 1-3 Alkyl radical, C 1-3 Hydroxyalkyl radical, C 1-3 Haloalkyl, C 1-3 Alkoxy radical, C 1-3 Haloalkoxy, -C (= O) O-C 1-3 Alkyl or-S (= O) 2 -C 1-3 Alkyl substituents.
- The compound, tautomer, deuteron or pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein R is 2 Selected from halogen, C 1-3 Alkyl or C 1-3 An alkoxy group; preferably chlorine, methyl or methoxy.
- The compound of any one of claims 1-6, a tautomer, a deutero-compound, or a pharmaceutically acceptable salt thereof, selected from compounds represented by general formula (IA):
wherein,X 1 is selected from N or CH;X 2 is selected from N or CH;R 3 is selected from C 1-6 Alkyl, - (C) 1-4 Alkylene radical) 0-1 -Cyc、-O-(C 1-4 Alkylene radical) 0-1 -Cyc、-S-(C 1-4 Alkylene radical) 0-1 -Cyc、-NH-(C 1-4 Alkylene radical) 0-1 -Cyc、-NH-C 1-6 Alkyl, -N (C) 1-6 Alkyl radical) 2 、-O-C 1-6 Alkyl or-S-C 1-6 Alkyl radical, R 3 Optionally unsubstituted or further substituted by one or more R 4 Substituted by a substituent;cyc is selected from C 3-10 Cycloalkyl, 3-to 10-membered heterocyclic group, C 6-10 Aryl or 5-to 10-membered heteroaryl, said C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl or 5-to 10-membered heteroaryl unsubstituted or substituted by 1,2 or 3 substituents R 5 Substituted;R 4 or R 5 Each independently selected from H, hydroxy, amino, halogen, cyano, nitro, -OR a 、-SR a 、＝O、＝S、-C(O)R a 、-C(S)R a 、-C(O)OR a 、-C(S)OR a 、-C(O)N(R a ) 2 、-N(R a ) 2 、-S(O) 2 R a 、-O-S(O 2 )OR a 、-O-S(O) 2 R a Or R a Said R is a Each independently selected from H, C 1-6 Alkyl or C 3-6 Cycloalkyl radical, R a Unsubstituted or further substituted by one or more groups selected from halogen, hydroxy, C 1-3 Alkyl or cyano;R 2 selected from hydrogen, halogen, cyano, C 1-3 Alkyl radical, C 1-3 Alkoxy radical, C 2-4 Alkenyl, halo C 2-4 Alkenyl or C 2-4 Alkynyl. - A compound, tautomer, deuteron, or pharmaceutically acceptable salt thereof, selected from:
- a process for the preparation of a compound of general formula (I), a tautomer, a deuteron, or a pharmaceutically acceptable salt thereof, as claimed in claim 1, which comprises:
reacting the compound of the general formula (II) under an acidic condition to obtain a compound of the general formula (I),wherein R is 1 And R 2 Is as defined in claim 1. - A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 8 and at least one pharmaceutically acceptable excipient.
- Use of a compound according to any one of claims 1 to 8 or a pharmaceutical composition according to claim 9 for the manufacture of a medicament.
- A method of treating and/or preventing a disease comprising administering to a subject a therapeutically effective amount of a compound of any one of claims 1-8 or a pharmaceutical composition of claim 9.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020106465629 | 2020-07-07 | ||
| CN202010646562 | 2020-07-07 | ||
| CN202010768662 | 2020-08-03 | ||
| CN2020107686629 | 2020-08-03 | ||
| PCT/CN2021/103508 WO2022007677A1 (en) | 2020-07-07 | 2021-06-30 | Cd73 inhibitor and application in pharmaceutical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115702150A true CN115702150A (en) | 2023-02-14 |
Family
ID=79553630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180043145.8A Pending CN115702150A (en) | 2020-07-07 | 2021-06-30 | CD73 inhibitor and application thereof in medicine |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115702150A (en) |
| WO (1) | WO2022007677A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3191829A1 (en) * | 2020-09-08 | 2022-03-17 | Hao Wu | Cd73 inhibitor and application thereof in medicine |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180100638A (en) * | 2016-01-08 | 2018-09-11 | 아르커스 바이오사이언시즈 인코포레이티드 | 5'-nucleotidase, modulator of ecto, and uses thereof |
| TWI702954B (en) * | 2018-03-01 | 2020-09-01 | 美商美國禮來大藥廠 | Cd73 inhibitors |
-
2021
- 2021-06-30 CN CN202180043145.8A patent/CN115702150A/en active Pending
- 2021-06-30 WO PCT/CN2021/103508 patent/WO2022007677A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022007677A1 (en) | 2022-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105524048B (en) | As the indazole compounds of FGFR kinase inhibitor and its preparation and application | |
| TWI757256B (en) | Inhibitors of ret | |
| KR102194646B1 (en) | Pyrimidine-2,4-diamine derivatives for treatment of cancer | |
| EP3381896B1 (en) | Biphenyl compound or salt thereof | |
| ES2426482T3 (en) | IGF-1R inhibitor | |
| CN112390796B (en) | KRAS G12C inhibitor and application thereof in medicine | |
| WO2018028438A1 (en) | Heterocyclic compound as fgfr inhibitor | |
| EA007298B1 (en) | Heteroalkyl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors) | |
| AU2006237920A1 (en) | Nitrogen-containing heterocyclic compound | |
| US6200982B1 (en) | Substituted 1H-pyridinyl-2-ones as GABAA-α 2/3 ligands | |
| TW202041498A (en) | Compounds for inhibiting pge2/ep4 signaling, preparation method thereof and use in medicine | |
| CN115702150A (en) | CD73 inhibitor and application thereof in medicine | |
| CN116348118A (en) | CD73 inhibitor and application thereof in medicine | |
| CN112851668A (en) | ATR inhibitor and application thereof in medicine | |
| EP4132908A1 (en) | Indole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd) | |
| JP2012211085A (en) | Hedgehog signal inhibitor | |
| WO2020057669A1 (en) | Aromatic heterocyclic compound with kinase inhibitory activity | |
| CN110407854B (en) | Novel tetracyclic compounds | |
| CN117510503A (en) | Tyrosine threonine kinase PKMYT1 inhibitor | |
| CN114057693A (en) | CD73 inhibitor and application thereof in medicine | |
| CN101466678B (en) | Substituted 3-cyanopyridines as protein kinase inhibitors | |
| KR102606167B1 (en) | Fluorine-containing substituted benzothiophene compounds, pharmaceutical compositions and applications thereof | |
| CN116867787A (en) | Pyrazolo [3,4-d ] pyrimidin-3-one derivatives | |
| CN113372334A (en) | 2- (4-methionyl) anilino-4-amino-5-trifluoromethylpyrimidine derivatives and application thereof | |
| CN114790197A (en) | CD73 inhibitor and application thereof in medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |